Document:

<PAGE>

                                                                  EXHIBIT 10.5.4

                           EXCLUSIVE LICENSE AGREEMENT

                                     Between

                    President and Fellows of Harvard College

                                       And

                                  NanoSys, Inc

                             Re: Harvard Case #2058

         In consideration of the mutual promises and covenants set forth below,
         the parties hereto agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

         As used in this Agreement, the following terms shall have the following
         meanings:

1.1      ACADEMIC RESEARCH PURPOSES: use of PATENT RIGHTS solely for academic
         non-commercial research or other not-for-profit scholarly purposes,
         which use is undertaken at a non-profit or governmental institution.
         ACADEMIC RESEARCH PURPOSES does not include selling products covered by
         PATENT RIGHTS or using PATENT RIGHTS in researching, developing,
         producing or manufacturing products for sale, or performance of
         services for a fee or other financial consideration. It is understood
         that using the PATENT RIGHTS to conduct normal research activities at
         non-profit or governmental institution is within the defined term of
         ACADEMIC RESEARCH PURPOSES.

1.2      AFFILIATE: any entity which controls, is controlled by, or is under
         common control with a party. An entity shall be regarded as in control
         of another entity for purposes of this definition if it owns or
         controls at least fifty percent (50%) of the shares entitled to vote in
         the election of directors (or in the case of an entity that is not a
         corporation, for the election of the corresponding managing authority).
         Unless otherwise specified, the term LICENSEE includes AFFILIATES.

1.3      FIELD: All fields of use.

1.4      HARVARD: President and Fellows of Harvard College, a nonprofit
         Massachusetts educational corporation having offices at the Office for
         Technology and Trademark

<PAGE>

         Licensing, Holyoke Center, Suite 727, 1350 Massachusetts Avenue,
         Cambridge, Massachusetts 02138.

1.5      LICENSED PROCESSES: methods, processes or procedures covered by at
         least one VALID CLAIM included within the PATENT RIGHTS.

1.6      LICENSED PRODUCTS: products covered by at least one VALID CLAIM
         included within the PATENT RIGHTS or products made in accordance with
         LICENSED PROCESSES.

1.7      LICENSEE: Nanosys, Inc., a corporation organized under the laws of
         Delaware having its principal offices at 2625 Hanover Street, Palo
         Alto, CA 94304

1.8      NET SALES: the amounts actually received for sales, leases, or other
         dispositions of LICENSED PRODUCTS to non-AFFILIATE third parties, less:

         (a) customary [*** Redacted];

         (b) amounts [*** Redacted] by reason of [*** Redacted];

         (c) to the extent separately as stated on purchase orders, invoices, or
             other documents of  sale: (i) [*** Redacted] levied on the
             production, sale, transportation, delivery, importation,
             exportation, or use of LICENSED PRODUCTS; (ii) charges for [***
             Redacted] provided by third parties, including any [*** Redacted]
             thereon.

         NET SALES also includes the fair market value of any non-cash
         consideration received for the sale, lease or other disposition of
         LICENSED PRODUCTS to non-AFFILIATE third parties; provided NET SALES
         shall not include any [*** Redacted], payments in consideration for the
         [*** Redacted] to the intellectual property of LICENSEE or third
         parties, including the [*** Redacted] hereunder, bona fide [***
         Redacted] made in good faith and any payments for [*** Redacted].

         In the event that a LICENSED PRODUCT is sold or leased as a combination
         product containing the LICENSED PRODUCT and one or more other
         components, NET SALES shall be calculated by multiplying the gross
         amount invoiced for the sale of the combination product by the fraction
         [*** Redacted] where A is the [*** Redacted] price of the LICENSED
         PRODUCT sold separately by LICENSEE, and B is the [*** Redacted] of
         such other components of the combination products sold separately by
         LICENSEE during the relevant royalty payment period.  In the event a
         substantial number of such separate sales were not made during the
         relevant royalty period, then NET SALES shall be reasonably allocated
         by LICENSEE between such LICENSED PRODUCT and such other components of
         the combination based on their relative importance or value; provided
         that such LICENSED PRODUCT and such other components shall not be
         considered a "combination product" unless such LICENSED PRODUCT is
         offered for sale or marketed by LICENSEE separately as well as
         together. If LICENSEE does so allocate, LICENSEE shall promptly deliver
         to HARVARD a written report providing a detailed explanation of how
         LICENSEE determined said relative importance or value. All such reports
         shall be deemed Confidential Information of LICENSEE subject to Section
         11.1. In the event that HARVARD disagrees with the determination made
         by LICENSEE of said allocation of importance or value, HARVARD shall so
         notify LICENSEE in writing, and a representative of LICENSEE and a
         representative of HARVARD shall meet in order to discuss and resolve
         such disagreement. If such disagreement cannot be resolved within sixty
         (60) days, such disagreement shall be subject to resolution in
         accordance with Section 11.10.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                               2

<PAGE>

1.9      PATENT RIGHTS: PATENT RIGHTS shall include (i) the applications and
         patents as listed in Appendix A of this Agreement, (ii) any foreign
         counterparts to such patents and patent applications, (iii) the
         inventions described and claimed in the foregoing, (iv) any divisions-
         or continuations of the foregoing, (v) applications from which the
         patents and applications listed in Appendix A claim priority, and which
         have been abandoned, and (vi) specific claims of any
         continuations-in-part of the foregoing to the extent the specific
         claims are directed to subject matter described in the foregoing in a
         manner sufficient to support such specific claims under 35 U.S.C. and
         to the extent Licensable by HARVARD; claims in said
         continuations-in-part covering minor improvements over the claims of
         parent patent applications may, at HARVARD'S discretion, be included in
         PATENT RIGHTS by amendment of this Agreement for no increase in the
         royalties of Article IV, (vi) all patents issuing on any of the
         foregoing, and (vii) registrations, renewals, reissues, reexaminations,
         extensions or patents of addition of any kind with respect to any of
         such patents. For purposes of this Agreement "Licensable" shall mean
         those claims of continuations-in-part filed after the Effective Date
         for which HARVARD has sole ownership (or has been granted the sole
         right to license by a co-owner) and where there are no obligations to
         grant licenses to a third party as the result of research support
         provided to one or more of the inventors.

1.10     SERVICE INCOME: the financial consideration actually received for the
         utilization of LICENSED PRODUCTS or LICENSED PROCESSES by LICENSEE
         which is contracted for by a non-AFFILIATE third party, less the
         deductions stated in Sections 1.8(a), (b) and (c); provided, however,
         that such amounts shall only be included in SERVICE INCOME if LICENSEE
         does not [*** Redacted] with respect to the PATENT RIGHTS licensed in
         this Agreement on the NET SALE of such LICENSED PRODUCTS or the NET
         SALE of LICENSED PRODUCTS made in accordance with such use of the
         LICENSED PROCESSES. SERVICE INCOME shall specifically exclude any [***
         Redacted] payments in consideration for the [*** Redacted] of the
         LICENSEE or third parties, including the sublicensing of rights
         hereunder, [*** Redacted] made in good faith and any [*** Redacted].

         In the event that any service contemplated hereunder includes any
         services other than the utilization of a [*** Redacted] or [***
         Redacted] LICENSEE shall in good faith determine the portion of the
         payments received for such service that are intended as consideration
         for the utilization of LICENSED PRODUCTS or LICENSED PROCESSES by
         LICENSEE, and such portion shall be used to determine the SERVICE
         INCOME for such service. In such event, LICENSEE shall promptly deliver
         to HARVARD a written report detailing such calculation, together with a
         copy of the applicable provisions of the agreements related to such
         service.  All such reports and provisions of agreements shall be deemed
         Confidential Information of LICENSEE subject to Section 11.1.  In the
         event that HARVARD disagrees with the determination made by LICENSEE of
         SERVICE INCOME for such service, HARVARD shall so notify LICENSEE in
         writing, and a representative of LICENSEE  and a representative of
         HARVARD shall meet in order to discuss and resolve such disagreement.
         If such disagreement cannot be resolved within sixty (60) days, such
         disagreement shall be subject to resolution in accordance with
         Section 11.10.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                               3

<PAGE>

1.11     SUBLICENSE INCOME: the amount paid to LICENSEE by a third party (other
         than an AFFILIATE of LICENSEE for the granting of a sublicense under
         section 3.1, including but not limited to (i) [*** Redacted] (ii) [***
         Redacted] (iii) [*** Redacted] and (vi) the [*** Redacted] in cash of
         any non-cash consideration for such sublicense, but specifically
         excluding any [*** Redacted] payments in consideration for the [***
         Redacted], [*** Redacted] and any payments for products purchased or
         services performed. It is understood and agreed that sublicense income
         received by LICENSEE shall be net of withholding taxes.

         If LICENSEE sublicenses [*** Redacted] to a third party and at the same
         time also grants such third party rights to [*** Redacted] or
         LICENSEE's in licensed non-HARVARD technologies, then all compensation
         received from the third party for such rights shall be combined and
         [*** Redacted] that would constitute SUBLICENSE INCOME  under Section
         1.11 and shall promptly deliver to HARVARD a written report detailing
         such calculation, together with a copy of the applicable provisions of
         the agreements with the third party.  All such reports and provisions
         of agreements shall be deemed Confidential Information of LICENSEE
         subject to Section 11.1.  In the event that HARVARD disagrees with the
         determination made by LICENSEE of SUBLICENSE INCOME, HARVARD shall so
         notify LICENSEE in writing, and a representative of LICENSEE and a
         representative of HARVARD shall meet in order to discuss and resolve
         such disagreement. If such disagreement cannot be resolved within sixty
         (60) days, such disagreement shall be subject to resolution in
         accordance with Section 11.10.

1.12     TERRITORY: Worldwide.

1.13     VALID CLAIM: either (i) a claim of an issued patent that has not
         expired or been held unenforceable or invalid by an agency or a court
         of competent jurisdiction, and which has not been admitted to be
         invalid or unenforceable through reissue, disclaimer or otherwise;
         provided, however, that if the holding of such court or agency is later
         reversed by a court or agency with overriding authority, the claim
         shall be reinstated as a Valid Claim with respect to Net Sales made
         after the date of such reversal, or (ii) a claim of a pending patent

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                               4

<PAGE>

         application that has not been abandoned or finally rejected without the
         possibility of appeal or re-filing and that has been pending for less
         than seven (7) years from its priority date, and is being actively
         prosecuted in good faith.

1.14     The terms "Public Law 96-517" and "Public Law 98-620" include all
         amendments to those statutes.

1.15     The terms "sold" and "sell" include, without limitation, leases and
         other dispositions and similar transactions.

1.16     RELATED LICENSE AGREEMENTS: Other patent license agreements between
         LICENSEE and HARVARD licensing patent rights known internally at
         HARVARD as Case #1852, #1765, #1923, #1924, #1988, #1678, #1641, #1489,
         #1352, #1243, #1137, #1816, #1685, #1935, #2058 to LICENSEE.

1.17     DEVELOPMENT PAYMENTS: DEVELOPMENT PAYMENTS shall mean (a) any payments,
         in consideration for, or to support, research and/or development
         efforts by LICENSEE to develop inventions claimed in PATENT RIGHTS and
         (b) any reimbursement of LICENSEE'S patent expenses concerning PATENT
         RIGHTS.

                                   ARTICLE II
                                    RECITALS

2.1      HARVARD is owner (or HARVARD will be owner) by assignment from
         Charles Lieber, Mark S. Gudiksen, Lincoln J. Lauhon, Jianfeng Wang,
         Xiangfeng Duan, Yi Cui, Yu Huang, Hongkun Park, Qingqiao Wei, Wenjie
         Liang, Deli Wang, and Zhaohui Zhong of HARVARD and the University of
         Southhampton of their entire right, title and interest in the United
         States Patent Application Serial Number 10/152,490, filed May 21, 2002,
         and 10/196,337 filed July 16th, 2002, and corresponding International
         Patent Application Serial No. PCT/US 0216133, filed May 21, 2002, all
         entitled "Nanoscale Wires and Related Devices", and the foreign patent
         applications corresponding thereto, and in the inventions described and
         claimed therein. The University of Southhampton was an owner by
         assignment from David C. Smith, and has assigned its interest to
         HARVARD, a copy of said assignment is attached in Appendix C.

2.2      HARVARD has the authority to issue licenses under PATENT RIGHTS.

2.3      HARVARD is committed to the policy that ideas or creative works
         produced at HARVARD should be used for the greatest possible public
         benefit, and believes that every reasonable incentive should be
         provided for the prompt introduction of such ideas into public use, all
         in a manner consistent with the public interest.

2.4      LICENSEE intends to use commercially reasonable efforts to develop the
         invention(s), and to bring to market at least one product falling
         within the definition of LICENSED PRODUCT or otherwise embodying the
         subject matter described or claimed in the patent rights licensed under
         such agreements.

                                                                               5
<PAGE>

2.5      LICENSEE is desirous of obtaining an exclusive license in the TERRITORY
         in order to practice the above-referenced invention covered by PATENT
         RIGHTS in the United States and in certain foreign countries, and to
         manufacture, use and sell in the commercial market the products made in
         accordance therewith, and HARVARD is desirous of granting such a
         license to LICENSEE in accordance with the terms of this Agreement.

                                   ARTICLE III
                                 GRANT OF RIGHTS

3.1      HARVARD hereby grants to LICENSEE and LICENSEE accepts, subject to the
         terms and conditions hereof, an exclusive license (except as set forth
         in Sections 3.2(a) and 3.2(b)) under PATENT RIGHTS in the TERRITORY and
         in the FIELD (i) to make and have made, to use and have used, to sell
         and have sold, to offer for sale, import, export, or otherwise
         distribute the LICENSED PRODUCTS, (ii) to practice the LICENSED
         PROCESSES, and (iii) to otherwise fully exploit the PATENT RIGHTS, and
         (iv) to have the foregoing performed on behalf of LICENSEE by a third
         party, in each case for the life of the PATENT RIGHTS. The foregoing
         license under PATENT RIGHTS shall include the full right to grant
         sublicenses, and LICENSEE shall promptly provide copies of any
         sublicenses of PATENT RIGHTS to HARVARD for its review. Unless HARVARD
         has rendered the license under PATENT RIGHTS non-exclusive under
         Section 3.2(c), and with the exception of rights already granted to
         Nantero, Inc., under HARVARD Case #1641, as provided in Section
         3.2(b)(ii), below, HARVARD agrees that it will not grant licenses under
         PATENT RIGHTS to others nor make, use, sell, offer for sale, import or
         otherwise exploit PATENT RIGHTS itself except as required by HARVARD'S
         obligations in Section 3.2(a) or as permitted in Sections 3.2(b)(i) and
         3.2(f).

3.2      The granting and exercise of this license is subject to the following
         conditions:

         (a)      HARVARD'S "Statement of Policy in Regard to Inventions,
                  Patents and Copyrights," dated August 10, 1998, Public Law
                  96-517 and Public Law 98-620, and HARVARD'S obligations under
                  prior or current agreements with other sponsors of research
                  and, with regard to continuations-in-part contained in the
                  PATENT RIGHTS, any future agreements with other sponsors of
                  research related to such continuations-in-part. Any right
                  granted in this Agreement greater than that permitted under
                  Public Law 96-517, or Public Law 98-620, shall be subject to
                  modification to the extent required to conform to the
                  provisions of those statutes.

         (b)      (i) HARVARD reserves the right to make and use, and grant to
                  other non-profit or governmental institutions non-exclusive
                  licenses to make and use, in each case solely for ACADEMIC
                  RESEARCH PURPOSES the subject matter described and claimed in
                  PATENT RIGHTS. HARVARD shall promptly notify LICENSEE of any
                  rights granted to any third party (other than the U.S.
                  government) under Sections 3.2(a) and (b).

         (c)      (ii) LICENSEE expressly recognizes that Nantero, Inc.
                  ("NANTERO") currently has a limited license under PATENT
                  RIGHTS, to the extent PATENT RIGHTS are included in NANTERO'S
                  co-exclusive license under the patent rights comprising

                                                                               6

<PAGE>

                 HARVARD case #1641 (but not to practice any technology
                 of PATENT RIGHTS that is not within the technology of HARVARD
                 case #1641).

         (d)     LICENSEE shall use commercially reasonable efforts to effect
                 introduction into the commercial market at least one product
                 falling within the definition of LICENSED PRODUCT or otherwise
                 embodying the subject matter described or claimed in PATENT
                 RIGHTS within seven and one half (7.5) years of the effective
                 date of this Agreement; thereafter, until the expiration of
                 this Agreement, LICENSEE shall use commercially reasonable
                 efforts to endeavor to keep any such product reasonably
                 available to the public so long as it shall be a sound and
                 reasonable commercial practice to do so.

                 At any time after seven and one half (7.5) years from the
                 effective date of this Agreement, HARVARD may render this
                 license non-exclusive if LICENSEE has not, either by itself or
                 through a sublicensee:

                   (i)    introduced into commercial use at least one product
                          falling within the definition of LICENSED PRODUCT or
                          made by a LICENSED PROCESS; and

                   (ii)   used commercially reasonable efforts to put the
                          licensed subject matter into commercial use as broadly
                          as commercially reasonable in one or more of the
                          countries hereby licensed, directly or through a
                          sublicense, as described in LICENSEE'S development
                          plan required by Paragraph 5.1 (b);and

                   (iii)  used commercially reasonable efforts to keep products
                          falling within the definition of LICENSED PRODUCT or
                          otherwise embodying the subject matter described or
                          claimed in PATENT RIGHTS reasonably available to the
                          public so long as it shall be a sound and reasonable
                          commercial practice to do so; and

                   (iv)   engaged in research, development, manufacturing,
                          marketing or sublicensing activity that is
                          commercially reasonably appropriate to achieving
                          Section 3.2(d)(ii) or 3.2(d)(iii).

         (e)     In all sublicenses granted by LICENSEE hereunder, LICENSEE
                 shall include a requirement that the sublicensee use
                 commercially reasonable efforts to put the subject matter of
                 the sublicense into commercial use, provided that such
                 sublicensee is authorized to develop and sell to the public a
                 new product covered by PATENT RIGHTS on its own behalf.
                 LICENSEE shall further provide that such sublicenses are
                 subject and subordinate to the terms and conditions of this
                 Agreement, except for the rate of royalty on NET SALES paid by
                 such sublicensee to the LICENSEE. Copies of all sublicense
                 agreements hereunder shall be provided promptly to HARVARD.
                 Such copies of sublicense agreements may be provided to
                 HARVARD in redacted form, provided that such copies contain
                 all relevant terms necessary for HARVARD to monitor LICENSEE'S
                 compliance with the terms of this Agreement.

                                                                               7

<PAGE>

                  Unredacted copies of said sublicense agreements shall be made
                  available for review by HARVARD or its representatives at
                  LICENSEE'S Medford, MA facility, or whichever facility is
                  closest to HARVARD, within one week, of HARVARD'S request. All
                  sublicense agreements of LICENSEE provided to HARVARD shall be
                  deemed Confidential Information of LICENSEE subject to Section
                  11.1.

         (f)      At any time five (5) years after the effective date of this
                  Agreement, if LICENSEE is unable or unwilling to grant
                  sublicenses, either as suggested by HARVARD or by a potential
                  sublicensee or otherwise, then HARVARD may directly license
                  such potential sublicensee, but only if: (i) LICENSEE is not
                  currently pursuing development of LICENSED PRODUCTS for the
                  same application, or an application that is reasonably
                  competitive with the application as contemplated by the
                  potential sublicensee, as demonstrated by annual progress
                  reports from LICENSEE required by Paragraph 5.2, or the
                  research and development plan required by Paragraph 5.1(b) of
                  this agreement or within a one-year period LICENSEE makes a
                  commitment to do so , said commitment being satisfied by a
                  written research and development plan, acceptable to HARVARD
                  and said acceptance given within the one-year period, said
                  acceptance not to be unreasonably denied. (if, in subsequent
                  reports by LICENSEE to HARVARD as required under Section 5.2,
                  LICENSEE fails to develop any applications according to the
                  research and development plan, as potentially amended
                  according to Section 5.2, such applications become subject to
                  this Paragraph); (ii) the granting of such a license by
                  HARVARD to the potential sublicensee will increase the
                  availability of useful products to the public, and (iii)
                  HARVARD notifies LICENSEE of its intention to grant such
                  license and permits LICENSEE a reasonable period to negotiate
                  a sublicense on its own, said reasonable period, unless
                  otherwise agreed to by the Parties, shall be no less than 6
                  months, nor greater than 12 months.

         (g)      To the extent required by law, until this license is rendered
                  non-exclusive in the United States under Section 3.2 (d),
                  LICENSEE shall cause any LICENSED PRODUCT produced for sale in
                  the United States to be manufactured substantially in the
                  United States.

         (h)      HARVARD recognizes that LICENSEE'S success in meeting the
                  obligations set forth in this paragraph may be enhanced by
                  consultation with the inventor(s) of the PATENT RIGHTS.
                  Accordingly, Harvard will use reasonable efforts to make such
                  inventors reasonably available to LICENSEE for such
                  consultation.

3.3      All rights reserved to the United States Government and others under
         Public Law 96-517, and Public Law 98-620, shall remain and shall in no
         way be affected by this Agreement.

3.4      HARVARD shall promptly notify LICENSEE when any new patent or patent
         application arises from (i) research conducted in the laboratory of Dr.
         Lieber or Dr. Park, or (ii) improvements made by HARVARD under the
         direction of Dr. Lieber or Dr. Park on the subject matter described in
         PATENT RIGHTS. If LICENSEE so requests and the intellectual property is
         available for licensing, HARVARD will evaluate in good faith LICENSEE'S
         proposal along with proposals received from any third parties. Any
         decision to grant a license to LICENSEE shall be subject to approval by
         HARVARD'S Committee

                                                                               8

<PAGE>

         on Patents and Copyrights. In the event LICENSEE and HARVARD cannot
         agree on terms for a license to any new intellectual property which is
         dominated by PATENT RIGHTS, HARVARD shall not offer any third party
         terms more favorable, in toto, than the terms offered to LICENSEE.

                                   ARTICLE IV
                                    ROYALTIES

4.1      LICENSEE shall owe to HARVARD a non-refundable license royalty fee in
         the sum of [*** Redacted] ($[*** Redacted]) dollars upon execution of
         this Agreement, which shall be payable within thirty days of this
         Agreement becoming effective.

4.2      As consideration for the rights granted hereunder, LICENSEE shall pay
         to HARVARD a non-refundable fee in the form of stock of LICENSEE as
         follows:

                    (i)    LICENSEE shall issue to HARVARD and HARVARD shall
                           purchase ten thousand (10,000) fully vested shares,
                           at a price per share of $0.19 per share and an
                           aggregate value of $1,900.00 of LICENSEE'S common
                           stock upon execution of this Agreement, provided,
                           however, that HARVARD shall be subject to and enter
                           into (1) appropriate agreements and related documents
                           as required of other stockholders of LICENSEE,
                           including without limitation a Common Stock Purchase
                           Agreement, and (2) a Voting Agreement by and among
                           the LICENSEE, HARVARD and certain other holders of
                           common stock of LICENSEE dated as of even date
                           hereof.

                    (ii)   HARVARD'S ownership rights to Shares shall not be
                           affected should the license pursuant to this
                           Agreement be terminated by LICENSEE or HARVARD.

4.3      (a) LICENSEE shall pay to HARVARD during the term of this Agreement a
         royalty on NET SALES by LICENSEE according to the following schedule:

           (i)    [*** Redacted]% of NET SALES by LICENSEE in [*** Redacted]
                  applications;

           (ii)   [*** Redacted]% of NET SALES by LICENSEE in [*** Redacted]
                  applications; or

           (iii)  [*** Redacted]% of NET SALES by LICENSEE in [*** Redacted]
                  excluding [*** Redacted] applications and [*** Redacted]
                  applications.

         In the event, any NET SALES by LICENSEE reasonably falls within more
         than one of categories (i) to (iii) above, LICENSEE shall pay to
         HARVARD the lowest applicable royalty set forth in such categories.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                               9

<PAGE>

         (b)      For each LICENSED PRODUCT sold by LICENSEE, LICENSEE may
                  credit up to [*** Redacted] of royalties that LICENSEE is
                  paying to third parties (or HARVARD under agreements not
                  included within section 4.3(c)) on LICENSEE'S sales of that
                  LICENSED PRODUCT, provided that the royalty paid to HARVARD
                  shall not be reduced below [*** Redacted] percent ([***
                  Redacted]%) of the NET SALES of that LICENSED PRODUCT for
                  which such third party royalties are being paid. LICENSEE may
                  only offset royalties owed under license agreements to third
                  parties where said license agreements provide for similar
                  offsets of comparable scale of third party royalties. Any such
                  offsets must be specifically and thoroughly reported in the
                  royalty reports required by Paragraph 5.4.

         (c)      In the event that sales of a LICENSED PRODUCT are subject to
                  the payment of royalties under one or more of the RELATED
                  LICENSE AGREEMENTS or any license agreements with HARVARD with
                  the same effective date as this Agreement, then the total
                  royalty payment due HARVARD under all such agreements
                  including this Agreement shall be at most the royalty payment
                  due under this Section 4.3 on such NET SALE, no matter how
                  many license agreements from HARVARD are involved, and
                  notwithstanding the terms of any such agreement. LICENSEE
                  shall notify HARVARD of the identity of each license agreement
                  that includes patent rights covering the product or process,
                  and HARVARD shall distribute the royalties evenly among such
                  agreements, including this Agreement.

         (d)      LICENSEE shall pay HARVARD [*** Redacted] percent ([***
                  Redacted]%) of SUBLICENSE INCOME received by LICENSEE for a
                  sublicense of PATENT RIGHTS. If compensation for such a
                  sublicense of PATENT RIGHTS is bundled with compensation
                  received for the sublicensing of the other HARVARD patents
                  rights or other HARVARD intellectual property licensed to
                  LICENSEE under the RELATED LICENSE AGREEMENTS or any
                  agreements with HARVARD having the same effective date as this
                  Agreement, then LICENSEE shall pay HARVARD at most the royalty
                  payment due under this Section 4.3(d) for such SUBLICENSE
                  INCOME no matter how many license agreements from HARVARD are
                  involved, and notwithstanding the terms of any such license
                  agreements. In such a case, LICENSEE shall notify HARVARD of
                  the identity of each license agreement involved and HARVARD
                  shall distribute the royalties equally among those license
                  agreements, including this Agreement.

         (e)      For provision of services under PATENT RIGHTS, LICENSEE shall
                  pay a royalty of [*** Redacted] percent ([*** Redacted]%) of
                  SERVICE INCOME received by LICENSEE from each and every third
                  party ("Third Party") to whom LICENSEE provides such services.
                  In the event any services from which SERVICE INCOME is derived
                  are subject to the payment of royalties under the RELATED
                  LICENSE AGREEMENTS or any agreement with HARVARD having the
                  same effective date as this Agreement, then the total royalty
                  due under all such agreements, including this Agreement, shall
                  be at most the royalty payment due under this Section 4.3 on
                  such services, no matter how many license agreements from
                  HARVARD are involved, and notwithstanding the terms of any
                  such license agreements. In such event, LICENSEE shall notify
                  HARVARD of the identity of each license agreement involved and
                  HARVARD shall distribute the royalties equally among those
                  license agreements, including this Agreement.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                              10

<PAGE>

         (f)      If the license pursuant to this Agreement is converted to a
                  non-exclusive one under Section 3.2(d) and if another
                  non-exclusive license to any of PATENT RIGHTS is granted or
                  otherwise exists for any field or territory, then the royalty
                  rate of this Agreement shall be adjusted so as not to exceed
                  the royalty rate payable by such other non-exclusive licensee
                  under such PATENT RIGHTS in such field or territory, provided
                  that LICENSEE agrees to amend this Agreement to include terms
                  requested by HARVARD that have been accepted by such other
                  non-exclusive licensee.

         (g)      On sales between LICENSEE and its AFFILIATES for resale, the
                  royalty shall be paid on the NET SALES of the AFFILIATE.

         (h)      In the event that more than one VALID CLAIM within PATENT
                  RIGHTS is applicable to any LICENSED PRODUCT subject to
                  royalties under this Section 4.3, then only one royalty shall
                  be paid to HARVARD in respect of such LICENSED PRODUCT. In no
                  event shall more than one royalty be due to HARVARD with
                  respect to any LICENSED PRODUCT unit; nor shall a royalty be
                  payable under this Section 4.3 with respect to sales of
                  LICENSED PRODUCTS for clinical trials nor the use of LICENSED
                  PRODUCTS or LICENSED PROCESSES by LICENSEE for such a purpose
                  whether or not in collaboration with a third party.

         4.4      No later than January 1 of each calendar year after the
                  effective date of this Agreement, LICENSEE shall pay to
                  HARVARD the following non-refundable license maintenance
                  royalty and/or advance on royalties. Such payments may be
                  credited against running royalties due for that calendar year
                  and Royalty Reports shall reflect such a credit. Such payments
                  shall not be credited against milestone payments (if any) nor
                  against royalties due for any subsequent calendar year.

<TABLE>
<S>                           <C>
January 1, 2004               $ [*** Redacted]
January 1, 2005               $ [*** Redacted]
January 1, 2006               $ [*** Redacted]
January 1, 2007               $ [*** Redacted]
January 1, 2008               $ [*** Redacted]
January 1, 2009               $ [*** Redacted]
January 1, 2010               $ [*** Redacted]
each January 1 thereafter     $ [*** Redacted]
</TABLE>

                                    ARTICLE V
                                    REPORTING

5.1      a) In compliance of earlier RELATED LICENSE AGREEMENTS, LICENSEE has
         provided to HARVARD a written research and development plan acceptable
         to LICENSEE'S investors under which LICENSEE intends to bring the
         subject matter of the

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                              11

<PAGE>

         earlier RELATED LICENSE AGREEMENTS (though not specifically of this
         Agreement) granted earlier into commercial use. Such plan included
         projections of sales and proposed marketing efforts.

         b) LICENSEE agrees to provide, no later than three (3) years after the
         effective date of this Agreement, a written research and development
         plan, under which LICENSEE intends to bring the subject matter of
         PATENT RIGHTS into commercial use. Such research and development plan
         shall be subject to the written approval or disapproval of HARVARD,
         which written approval shall not be unreasonably withheld. Failure to
         provide written disapproval within 60 days of receipt of such research
         and development plan shall constitute HARVARD'S approval in accordance
         with this section. Such a plan shall include a description of each
         LICENSED PRODUCT to be developed, a developmental timeline showing the
         technical, regulatory, business and marketing steps (benchmarks) needed
         to bring the LICENSED PRODUCT into commercial use and the resources in
         funds and personnel that LICENSEE will bring to bear for the successful
         accomplishment of each such step, and shall include projected sales and
         a proposed marketing effort

5.2      No later than sixty (60) days after June 30 of each calendar year,
         LICENSEE shall provide to HARVARD a written annual Progress Report
         describing progress on the commercialization of PATENT RIGHTS during
         the most recent twelve (12) period ending June 30, the amount of
         LICENSEE'S R&D spending relating to the subject matter described or
         claimed in PATENT RIGHTS during such time, and plans for the
         forthcoming year. If multiple technologies are covered by the license
         granted hereunder, the Progress Report shall provide the information
         set forth above for each technology. If progress differs from that
         anticipated in the plan required under Section 5.1(b), LICENSEE shall
         explain the reasons for the difference and, if appropriate or
         necessary, provide a modified research and development plan for
         HARVARD'S review and approval, such approval not to be unreasonably
         denied. It is understood that LICENSEE may provide one Progress Report
         covering all RELATED LICENSE AGREEMENTS.

5.3      LICENSEE shall report to HARVARD the date of its first NET SALE of a
         LICENSED PRODUCT (or the date of its first use of a LICENSED PROCESS
         from which SERVICE INCOME is derived) in each country within
         thirty (30) days of occurrence. It is understood that LICENSEE shall
         be obligated to report the date of first sale of LICENSED PRODUCTS (or
         the first commercial use of LICENSED PROCESSES) under this Section 5.3
         only once for each country.

5.4      (a) LICENSEE shall submit to HARVARD within sixty (60) days after
         each calendar half year ending June 30 and December 31, a Royalty
         Report setting forth, for the most recent half year that ended on June
         30 and December 31, at least the following information:

                  (i)      the number and identification of LICENSED PRODUCTS
                           sold by LICENSEE and its AFFILIATES that constitute a
                           NET SALE, in each country;

                                                                              12

<PAGE>

                  (ii)     total amounts received for such LICENSED PRODUCTS
                           sold by LICENSEE and its AFFILIATES;

                  (iii)    an accounting for all LICENSED PROCESSES used or sold
                           by LICENSEE and its AFFILIATES;

                  (iv)     deductions applicable to determine the NET SALES
                           thereof;

                  (v)      the amount of SUBLICENSE INCOME received by LICENSEE
                           from each sublicensee, and for each sublicensee the
                           categories of LICENSED PRODUCTS sold and gross sales
                           of each category;

                  (vi)     the amount of SERVICE INCOME received by LICENSEE;
                           and

                  (vii)    the amount of royalty due for such reporting period,
                           or, if no royalties are due to HARVARD for such
                           reporting period, the statement that no royalties are
                           due.

                  Such report shall be certified as correct by an officer of
                  LICENSEE and shall include a listing of all deductions from
                  royalties. It is understood that LICENSEE may submit one
                  Royalty Report covering all RELATED LICENSE AGREEMENTS.
                  However, the Royalty Report shall, for each type of income,
                  provide a detailed listing of the RELATED LICENSE AGREEMENTS
                  that are involved.

         (b)      LICENSEE shall pay to HARVARD with each such Royalty Report
                  the amount of royalty due with respect to such half year.
                  If multiple technologies are covered by the license granted
                  hereunder, LICENSEE shall specify which PATENT RIGHTS are
                  utilized for each category of LICENSED PRODUCTS and/or
                  LICENSED PROCESSES for which royalties are separately reported
                  in the Royalty Report.

         (c)      All payments due hereunder shall be deemed received when funds
                  are credited to HARVARD'S bank account and shall be payable by
                  check or wire transfer in United States dollars. Conversion of
                  foreign currency to U.S. dollars shall be made at the
                  conversion rate existing in the United States (as reported in
                  the New York Times or the Wall Street Journal) on the last
                  working day of each royalty period. No transfer, exchange,
                  collection or other charges shall be deducted from such
                  payments. If legal restrictions block the removal of local
                  currency from any country where a LICENSED PRODUCT is sold,
                  the royalties payable under this Agreement on NET SALES,
                  SERVICE INCOME and SUBLICENSING INCOME earned in such currency
                  in such country shall continue to be reported and accrued,
                  but will not be paid until such currency may be removed from
                  such country.

         (d)      All plans or reports received under Sections 5.1, 5.2, 5.3,
                  5.4 shall be deemed Confidential Information of LICENSEE
                  subject to Section 11.1; provided, however, that HARVARD may
                  disclose such information as required by law under Section
                  1l.l(b), and may include in its usual reports the annual
                  amounts of royalties paid.

                                                                              13

<PAGE>
         (e)      Late payments shall be subject to a charge of one and one-half
                  percent (1.5%) per month, or $250, whichever is greater.

5.5      In the event of acquisition, merger, change of corporate name, or
         change of make-up, organization, or identity, LICENSEE shall notify
         HARVARD in writing within [*** Redacted] days of such event.

5.6      If LICENSEE or any of its sublicensees does not qualify as a "small
         entity" as provided by the United States Patent and Trademark Office,
         LICENSEE must notify HARVARD immediately.

                                   ARTICLE VI
                                 RECORD KEEPING

6.1      LICENSEE shall keep accurate records (together with supporting
         documentation) of LICENSED PRODUCTS made, used or sold under this
         Agreement, sufficient to determine the amount of royalties due to
         HARVARD hereunder. Such records shall be retained for at least
         three (3) years following the end of the reporting period to which
         they relate. They shall be available during normal business hours for
         examination, upon HARVARD'S reasonable request, not more than once in
         any twelve (12) month period and upon at least twenty (20) days
         prior notice, by an independent accountant under a duty of
         confidentiality, selected by HARVARD and reasonably acceptable to
         LICENSEE, for the sole purpose of verifying reports and payments under
         Section 5.4. In conducting examinations pursuant to this Section,
         HARVARD'S accountant shall have access to records materially relevant
         to the calculation of royalties under Article IV.

6.2      HARVARD'S accountant shall only disclose to HARVARD whether the reports
         and payments of royalties hereunder are accurate, and the amount of the
         underreporting or underpayment of royalties by LICENSEE, if any.

6.3      Such examination by HARVARD'S accountant shall be at HARVARD'S expense,
         except that if such examination shows an underreporting or underpayment
         in excess of five percent (5%) for any twelve (12) month period, then
         LICENSEE shall pay the reasonable out-of-pocket cost of such
         examination as well as any additional sum that would have been payable
         to HARVARD had the LICENSEE reported correctly, plus interest on said
         sum at the rate of one and one-half percent (1.5%) per month.

                                   ARTICLE VII
               DOMESTIC AND FOREIGN PATENT FILING AND MAINTENANCE

7.1      Upon execution of this Agreement, LICENSEE shall reimburse HARVARD for
         all reasonable expenses HARVARD has incurred for the preparation,
         filing, prosecution and

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                              14

<PAGE>

         maintenance of PATENT RIGHTS. Thereafter, LICENSEE shall reimburse
         HARVARD for all such future expenses within [*** Redacted] days of
         receipt of invoices from HARVARD. Late payment of these invoices shall
         be subject to interest charges of one and one-half percent (1.5%) per
         month. HARVARD shall, in its sole discretion, be responsible for the
         preparation, filing, prosecution and maintenance of any and all patent
         applications and patents included in PATENT RIGHTS. HARVARD shall
         consult with LICENSEE as to the preparation, filing, prosecution and
         maintenance of such patent applications and patents and shall furnish
         to LICENSEE copies of documents relevant to any such preparation,
         filing, prosecution or maintenance.

         HARVARD shall be responsible for the preparation, filing, prosecution
         and maintenance of any and all patent applications and patents included
         in PATENT RIGHTS. HARVARD will instruct counsel to directly notify
         HARVARD and LICENSEE and provide them copies of any communications to
         and from the United States and foreign patent offices relating to said
         prosecution, and drafts of all communications to the various patent
         offices, and will instruct counsel to consider any comments on such
         drafts, so that LICENSEE will be informed and apprised of the
         continuing prosecution of patent applications in PATENT RIGHTS.
         LICENSEE shall have reasonable opportunity to participate in decision
         making on key decisions affecting filing, prosecution and maintenance
         of patents and patent applications in PATENT RIGHTS.

7.2      HARVARD and LICENSEE shall cooperate fully in the preparation, filing,
         prosecution and maintenance of PATENT RIGHTS and of all patents and
         patent applications licensed to LICENSEE hereunder, executing all
         papers and instruments or requiring members of HARVARD to execute such
         papers and instruments so as to enable HARVARD to apply for, to
         prosecute and to maintain patent applications and patents in HARVARD'S
         name in any country. Each party shall provide to the other
         prompt notice as to all matters which come to its attention and
         which may affect the preparation, filing, prosecution or maintenance of
         any such patent applications or patents. In particular, LICENSEE must
         immediately notify HARVARD if LICENSEE does not qualify as a "small
         entity" as provided by the United States Patent and Trademark Office.

7.3      LICENSEE may elect to surrender its rights to any patent or patent
         application within PATENT RIGHTS in any country upon sixty (60)
         days written notice to HARVARD. Such notice shall not relieve LICENSEE
         from responsibility to reimburse HARVARD for expenses under Section 7.1
         relating to the filing, prosecution or maintenance of such patent or
         patent application incurred prior to the receipt of the written notice
         by HARVARD (or a longer period if specified in LICENSEE'S notice).

                                  ARTICLE VIII
                                  INFRINGEMENT

8.1      With respect to any PATENT RIGHTS that have not been rendered
         non-exclusive under Section 3.2(d), LICENSEE shall have the right to
         enforce in its own name and at its own expense any patents within such
         PATENT RIGHTS. HARVARD agrees to notify

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                              15

<PAGE>

         LICENSEE promptly of each infringement of such patents of which HARVARD
         is or becomes aware.

8.2      (a)      If LICENSEE elects to commence an action as described above,
                  HARVARD may, to the extent permitted by law, elect to join as
                  a party in that action. Regardless of whether HARVARD elects
                  to join as a party, HARVARD shall cooperate fully with
                  LICENSEE in connection with any such action, including making
                  available relevant personnel, information, records, papers,
                  samples, specimens and other similar materials for the
                  purposes of such action as reasonably requested by LICENSEE
                  through the Office of Technology and Trademark Licensing at
                  HARVARD.

         (b)      If HARVARD elects to join as a party pursuant to Subsection
                  (a), HARVARD shall jointly control the action with LICENSEE.

         (c)      LICENSEE shall reimburse HARVARD for any out-of-pocket costs
                  HARVARD reasonably incurs, including reasonable attorneys'
                  fees, as part of an action brought by LICENSEE under Section
                  8.1, whether or not HARVARD becomes a co-plaintiff.

8.3      If LICENSEE elects to commence an action as described above and desires
         that HARVARD be responsible for some of its expenses as described
         immediately below, LICENSEE shall explain its strategy to HARVARD in
         any detail requested by HARVARD. If HARVARD approves of said action in
         writing, LICENSEE may deduct from its royalty payments to HARVARD with
         respect to the patent(s) subject to suit an amount not exceeding fifty
         percent (50%) of LICENSEE'S expenses and costs of such action,
         including reasonable attorneys' fees and reimbursement of amounts under
         Section 8.2(c) above; provided, however, that such reduction shall not
         exceed fifty percent (50%) of the total royalty due to HARVARD with
         respect to the patent(s) subject to suit for each calendar year. If
         such fifty percent (50%) of LICENSEE's expenses and costs exceeds the
         amount of royalties deducted by LICENSEE for any calendar year,
         LICENSEE may to that extent reduce the royalties due to HARVARD from
         LICENSEE in succeeding calendar years, but never by more than fifty
         percent (50%) of the total royalty due in any one year with respect to
         the patent(s) subject to suit.

8.4      Neither party may enter into a settlement, consent judgment or other
         voluntary final disposition of any suit under Section 8.1, 8.6, 8.7 and
         8.8 without the prior written consent of the other party, which consent
         shall not be unreasonably withheld.

8.5      Recoveries or reimbursements from actions commenced pursuant to this
         Article shall first be applied to reimburse LICENSEE and HARVARD for
         litigation costs not paid from royalties deducted by LICENSEE pursuant
         to Section 8.3. Any remaining recoveries or reimbursements shall be
         shared as follows: if HARVARD approved of said action(s) as described
         in Paragraph 8.3, 80% to LICENSEE and 20% to HARVARD, if HARVARD did
         not approve of said action(s) then any remaining recoveries shall be
         treated as net sales and LICENSEE shall pay an earned royalty of [***
         Redacted]% to HARVARD.

***  Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                              16

<PAGE>

8.6      If LICENSEE elects not to exercise its right to enforce the PATENT
         RIGHTS against any infringement pursuant to this Article, HARVARD may
         do so at its own expense, controlling such action and retaining all
         recoveries therefrom. LICENSEE shall cooperate fully with HARVARD in
         connection with any such action.

8.7      Without limiting the generality of Section 8.6, HARVARD may, at its
         election and by notice to LICENSEE, establish a time limit of one-
         hundred and eighty days for LICENSEE to decide whether to enforce the
         PATENT RIGHTS against any infringement of which HARVARD is or becomes
         aware. If, by the end of such one-hundred and eighty day period,
         LICENSEE has not (a) commenced such an action; (b) taken reasonable
         efforts to settle such infringement; or (c) provided HARVARD with a
         written report that provides LICENSEE'S plans to commence such action
         or settle such infringement in the future and the reasons for any
         proposed delay in commensing such action or settling such infringment,
         which report must be approved by HARVARD, which approval will not
         unreasonably be denied or delayed and which approval shall not be
         construed as giving approval for Paragraph 8.3 purposes, HARVARD may
         enforce the PATENT RIGHTS against such an infringement at its own
         expense, controlling such action and retaining all recoveries
         therefrom. Notwithstanding sections 8.6 and 8.7, HARVARD shall not
         bring any action alleging the infringement of PATENT RIGHTS against any
         sublicensee of LICENSEE under PATENT RIGHTS, without the consent of
         LICENSEE.

8.8      If a declaratory judgment action is brought naming LICENSEE as a
         defendant and alleging invalidity of any of the PATENT RIGHTS, if both
         parties agree, HARVARD may take over the sole defense of the action at
         its own expense. LICENSEE shall cooperate fully with HARVARD in
         connection with any such action.

                                   ARTICLE IX
                            TERMINATION OF AGREEMENT

9.1      The effective date of this Agreement shall be the date that both
         parties have signed the Agreement. This Agreement, unless terminated as
         provided herein, shall remain in effect until the last patent or patent
         application in PATENT RIGHTS has expired or been abandoned.

9.2      HARVARD may terminate this Agreement as follows:

         (a)      If LICENSEE does not make a payment due hereunder and fails to
                  cure such nonpayment (including the payment of interest in
                  accordance with Section 5.4(e)) within forty-five days after
                  the date of notice in writing of such non-payment by HARVARD.
                  If LICENSEE disputes the amount of such non-payment in writing
                  within such forty-five day period, HARVARD shall not have the
                  right to terminate this Agreement until it has been determined
                  in an arbitration proceeding under Section 11.10 below that
                  LICENSEE has failed to pay amounts owed hereunder, in which
                  case LICENSEE shall pay HARVARD'S expenses for the

                                                                              17

<PAGE>
                  arbitration, and thereafter Licensee does not cure such
                  failure within sixty (60) days after such determination. This
                  Section 9.2(a) shall not, however, suspend any obligation of
                  LICENSEE to compensate HARVARD for any undisputed amounts, as
                  provided for under any term of this Agreement, during the
                  pendency of the foregoing arbitration and cure period.

         (b)      If LICENSEE defaults in its obligations under Sections 11.2(c)
                  and 11.2(d) to procure and maintain insurance, and fails to
                  cure such breach within sixty (60) days after notice in
                  writing of such breach by HARVARD.

         (c)      If LICENSEE shall make an assignment for the benefit of
                  creditors, or shall have a petition in bankruptcy filed for or
                  against it, provided that such bankruptcy petition is not
                  dismissed within sixty (60) days after its filing. Such
                  termination shall be effective immediately upon HARVARD giving
                  written notice to LICENSEE.

         (d)      If LICENSEE is convicted of a felony within the United States
                  relating to the manufacture, use, or sale of LICENSED
                  PRODUCTS.

         (e)      Except as provided in Subsections (a), (b), (c), (d) above, if
                  LICENSEE materially breaches any obligations under this
                  Agreement and the breach has not been cured within ninety (90)
                  days after the date of notice in writing of such breach by
                  HARVARD. If LICENSEE disputes in writing that it has
                  materially breached this Agreement within such ninety (90) day
                  period, HARVARD shall not have the right to terminate this
                  Agreement until it has been determined in an arbitration
                  proceeding under Section 11.10 below that LICENSEE has
                  materially breached this Agreement, in which case LICENSEE
                  shall pay HARVARD'S expenses for the arbitration, and
                  thereafter Licensee does not cure such breach within sixty
                  (60) days after such determination. This Section 9.2(e) shall
                  not, however, suspend any obligation of LICENSEE to compensate
                  HARVARD for any undisputed amounts, as provided for under any
                  term of this Agreement, during the pendency of the foregoing
                  arbitration and cure period.

9.3      All sublicenses granted by LICENSEE under this Agreement in compliance
         with the terms and conditions hereof shall survive the termination of
         this Agreement upon the request of the party to whom such sublicense is
         granted, provided that such party agrees in writing that (i) it will
         pay all royalties or other amounts that otherwise would have been due
         thereafter under such sublicense directly to HARVARD rather than
         LICENSEE, and (ii) HARVARD shall not be held liable for the breach or
         the performance of any obligations stated in such sublicense unless
         such obligations have been expressly assumed in writing by HARVARD.

9.4      LICENSEE may terminate this Agreement by giving ninety (90) days
         advance written notice of termination to HARVARD. Upon termination,
         LICENSEE shall promptly submit a Royalty Report to HARVARD for the
         final reporting period and any royalty payments incurred during such
         reporting period, and any unreimbursed patent expenses

                                                                              18

<PAGE>

         under Section 7 that have been invoiced by HARVARD, shall become
         immediately payable with such Royalty Report.

9.5      Articles I, VI, IX, X and XI (except for Section 11.7) of this
         Agreement shall survive termination. Article VIII shall survive with
         respect to any infringement of third parties and/or any lawsuits filed
         by or against LICENSEE, prior to the termination of this Agreement. In
         the event this Agreement is terminated for any reason, LICENSEE may,
         within six months after the effective date of such termination, sell
         or otherwise dispose of all LICENSED PRODUCTS that LICENSEE may have on
         hand on the effective date of such termination, and fulfill any
         contracts requiring the use of LICENSED PRODUCTS and/or LICENSED
         PROCESSES that LICENSEE may have entered into prior to the date of such
         termination, subject to LICENSEE'S payment of amounts due to HARVARD
         under Section 4.3 of this Agreement.

                                    ARTICLE X
                         REPRESENTATIONS AND WARRANTIES

10.1     Except for the rights, if any, of the Government of the United States,
         HARVARD represents and warrants that:

         (a)      HARVARD is the owner of the entire right, title and interest
                  in and to the PATENT RIGHTS as they exist on the Effective
                  Date;

         (b)      HARVARD has the right and authority to enter into this
                  Agreement and grant the rights and licenses set forth herein,
                  including without limitation under PATENT RIGHTS;

         (c)      HARVARD has not previously granted, and will not grant in the
                  future, any rights in the PATENT RIGHTS that are inconsistent
                  with the rights and licenses granted to LICENSEE herein;

         (d)      To the best knowledge of HARVARD without having made an
                  investigation, as of the Effective Date, practice of
                  inventions within the PATENT RIGHTS does not infringe any
                  patent rights, trade secrets or other proprietary rights of
                  any third party,

         (e)      To the best knowledge of HARVARD, as of the Effective Date,
                  HARVARD does not own any rights in any other patent or patent
                  application, the claims of which would dominate the claims of
                  a patent or patent application within the PATENT RIGHTS or any
                  practice of PATENT RIGHTS. If HARVARD owns, now or thereafter,
                  any such rights in such patents or patent applications on
                  which Dr. Lieber or Dr. Park is an inventor, HARVARD will
                  negotiate in good faith to the extent it has the legal right
                  to do so with LICENSEE to grant LICENSEE rights to the extent
                  sufficient to practice PATENT RIGHTS, and at commercially
                  reasonable royalties.

         (f)      To the best knowledge of HARVARD, all prior and current
                  agreements between HARVARD and other sponsors of research
                  under which HARVARD has obligations relating to PATENT RIGHTS
                  are listed on Appendix C.

                                                                              19

<PAGE>

10.2     Except as set forth in this Agreement, HARVARD does not warrant the
         validity of the PATENT RIGHTS licensed hereunder and makes no
         representations whatsoever with regard to the scope of the licensed
         PATENT RIGHTS or that such PATENT RIGHTS may be exploited by LICENSEE,
         an AFFILIATE, or sublicensee without infringing other patents.

10.3     EXCEPT FOR THE WARRANTIES STATED IN THIS AGREEMENT, HARVARD EXPRESSLY
         DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS WARRANTIES AND MAKES NO
         EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY
         PARTICULAR PURPOSE OF THE PATENT RIGHTS OR INFORMATION SUPPLIED BY
         HARVARD, LICENSED PROCESSES OR LICENSED PRODUCTS CONTEMPLATED BY THIS
         AGREEMENT.

                                   ARTICLE XI
                                     GENERAL

11.1     (a)      The parties may, from time to time, in connection with this
                  Agreement disclose to each other Confidential Information. Any
                  Confidential Information shall be in writing and marked
                  "confidential" and disclosed only to the Office of Technology
                  and Trademark Licensing. As used in this Agreement,
                  "Confidential Information" of a party shall mean (i) any
                  information disclosed in writing by such party to the other
                  party, which is marked by such party with the legend
                  "CONFIDENTIAL" or other similar legend sufficient to identify
                  the information as its confidential information, (ii) any
                  information disclosed orally by such party to the other party
                  which is identified as confidential at the time of disclosure
                  and is confirmed as confidential in writing within thirty (30)
                  days after such time of disclosure, or (iii) any information
                  deemed Confidential Information under the terms of this
                  Agreement. With respect to categories (i) and (ii) above,
                  "Confidential Information" shall not include any information
                  that is: (1) already known to the receiving party at the time
                  of disclosure hereunder, or (2) now or hereafter becomes
                  publicly known other than through acts or omissions of the
                  receiving party, or (3) is disclosed to the receiving party by
                  a third party under no obligation of confidentiality to the
                  disclosing party or (4) is independently developed by the
                  receiving party without use of the Confidential Information of
                  the disclosing party.

         (b)         Each party shall maintain in confidence, and shall not use
                  for any purpose or disclose to any third party, the
                  Confidential Information of the other party. Notwithstanding
                  the foregoing, the receiving party may use or disclose the
                  Confidential Information of the disclosing party (i) to the
                  extent necessary to exercise its rights or fulfill its
                  obligations and/or duties under this Agreement, and (ii) to
                  comply with applicable law or governmental regulations or
                  court order, provided that the receiving party will give
                  reasonable advance notice to the disclosing party, and will
                  use its reasonable efforts to minimize the disclosure of
                  Confidential Information and to secure confidential treatment
                  of any Confidential Information disclosed.

                                                                              20

<PAGE>

         (c)      The royalty terms of this Agreement shall be deemed
                  "Confidential Information" of both parties. In addition to the
                  permissible disclosures set forth in subsection (b) above,
                  LICENSEE may disclose such terms in confidence to its
                  financial and legal advisors, consultants, potential or actual
                  investors, potential or actual merger or acquisition partners,
                  and others on a need-to-know basis.

11.2     (a)      LICENSEE shall indemnify, defend and hold harmless HARVARD and
                  its current or former and future directors, governing board
                  members, trustees, officers, faculty and employees
                  (collectively, the "INDEMNITEES"), from and against any claim,
                  lawsuit, cause of action , liability, cost, expense, damage,
                  deficiency, loss or obligation of any kind or nature
                  (including, without limitation, reasonable attorney's fees and
                  other costs and expenses of litigation) (collectively,
                  "Claims"), based upon, arising out of, or otherwise relating
                  to: LICENSEE'S or any sublicensee's performance of (or failure
                  to perform) any of its obligations under this Agreement or any
                  sublicense agreement, or the practice by LICENSEE or any
                  sublicensee of any right or license granted under this
                  Agreement or any sublicense agreement, or any product,
                  process, or service made, used or sold pursuant to any right
                  or license granted under this Agreement or any sublicense
                  agreement, including without limitation any Claim relating to
                  product liability (whether based on negligence or other tort,
                  warranty, strict liability, or any other theory), except to
                  the extent such Claims are directly attributable to
                  intentional misconduct of any INDEMNITEES. It shall be a
                  condition of the foregoing obligation that (i) LICENSEE
                  receives prompt notice of any such Claims; (ii) LICENSEE is
                  given the exclusive right to control the defense and
                  settlement of such Claims, provided that LICENSEE shall not
                  settle any such Claim without the prior written consent of
                  HARVARD, which consent shall not be unreasonably withheld; and
                  (iii) LICENSEE shall not be obligated to indemnify any
                  INDEMNITEE in connection with any settlement for any Claim
                  unless LICENSEE consents in writing to such settlement.

         (b)      LICENSEE shall, at its own expense, defend against any actions
                  brought or filed against any INDEMNITEE hereunder with respect
                  to the subject of indemnity contained herein, whether or not
                  such actions are rightfully brought.

         (c)      Beginning at the time any such product, process or service is
                  being commercially distributed or sold (other than for the
                  purpose of obtaining regulatory approvals) by LICENSEE or by a
                  SUBLICENSEE, AFFILIATE or agent of LICENSEE, LICENSEE shall,
                  at its sole cost and expense, procure and maintain commercial
                  general liability insurance in amounts not less than
                  $ [*** Redacted] per incident and $ [*** Redacted] annual
                  aggregate and naming the Indemnitees as additional insureds.
                  During clinical trials of any such product, process or
                  service, LICENSEE shall, at its sole cost and expense, procure
                  and maintain commercial general liability insurance in such
                  equal or lesser amount as HARVARD shall require, naming the
                  Indemnitees as additional insureds. Such commercial general
                  liability insurance shall provide: (i) product liability
                  coverage; and (ii) broad form contractual liability coverage
                  for LICENSEE'S indemnification under this Agreement. If
                  LICENSEE elects to self-insure all or part of the limits
                  described above (including deductibles or retentions

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                              21

<PAGE>

                  which are in excess of [*** Redacted] annual aggregate) such
                  self-insurance program must be acceptable to HARVARD and the
                  Risk Management Foundation of the Harvard Medical
                  Institutions, Inc. in their sole discretion. The minimum
                  amounts of insurance coverage required shall not be construed
                  to create a limit of LICENSEE'S liability with respect to its
                  indemnification under this Agreement.

         (d)      LICENSEE shall provide HARVARD with written evidence of such
                  insurance upon request of HARVARD. LICENSEE shall provide
                  HARVARD with written notice at least fifteen (15) days prior
                  to the cancellation, non-renewal or material change in such
                  insurance; if LICENSEE does not obtain replacement insurance
                  providing comparable coverage within such fifteen (15) day
                  period, HARVARD shall have the right to terminate this
                  Agreement in accordance with Section 9.2(b).

         (e)      LICENSEE shall maintain such commercial general liability
                  insurance beyond the expiration or termination of this
                  Agreement during: (i) the period that any product, process, or
                  service, relating to, or developed pursuant to, this Agreement
                  is being commercially distributed or sold by LICENSEE or by a
                  sublicensee, AFFILIATE or agent of LICENSEE; and (ii) a
                  reasonable period after the period referred to in Subsection
                  (e)(i) above which in no event shall be less than
                  fifteen (15) years.

11.3     Nothing in this Agreement shall be construed as conferring any right to
         use HARVARD's name or insignia, or any adaptation of them, or the name
         of any of HARVARD's inventors in any advertising, promotional or sales
         literature without the prior written approval of HARVARD, or the
         inventor in the case of the use of the name of an inventor.

11.4     Except as stated in this Section 11.4, without the prior written
         approval of HARVARD in each instance, neither this Agreement nor the
         rights granted hereunder shall be transferred or assigned in whole or
         in part by LICENSEE to any person whether voluntarily or involuntarily,
         by operation of law or otherwise. LICENSEE may transfer or assign this
         Agreement and all rights hereunder, upon notice to HARVARD but without
         its consent, to any entity that succeeds to all or substantially all of
         the business of LICENSEE to which this Agreements pertains, whether by
         merger, operation of law, purchase or sale of all or substantially all
         of LICENSEE's stock or assets or otherwise; provided that such assignee
         or transferee promptly agrees in writing to be bound by the terms and
         conditions of this Agreement. Subject to the foregoing, this Agreement
         shall be binding upon the respective successors, legal representatives
         and assignees of HARVARD and LICENSEE.

11.5     The interpretation and application of the provisions of this Agreement
         shall be governed by the laws of the Commonwealth of Massachusetts.

11.6     LICENSEE shall comply with all applicable laws and regulations. In
         particular, it is understood and acknowledged that the transfer of
         certain commodities and technical data is subject to United States laws
         and regulations controlling the export of such commodities and
         technical data, including all Export Administration Regulations of the
         United States Department of Commerce. These laws and regulations among
         other things, prohibit or require a license for the export of certain
         types of technical data to certain specified

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                              22

<PAGE>

         countries. LICENSEE hereby agrees and gives written assurance that it
         will comply with all United States laws and regulations controlling the
         export of commodities and technical data, that it will be solely
         responsible for any violation of such by LICENSEE or its AFFILIATES or
         sublicensees, and that it will defend and hold HARVARD harmless in the
         event of any legal action of any nature occasioned by such violation
         with respect to LICENSED PRODUCTS.

11.7     LICENSEE agrees: (i) to obtain all regulatory approvals required for
         the manufacture and sale of LICENSED PRODUCTS and LICENSED PROCESSES;
         and (ii) to mark LICENSED PRODUCTS with the numbers of the applicable
         patents within PATENT RIGHTS, to the extent required by law. LICENSEE
         also agrees to register or record this Agreement as is required by law
         or regulation in any country where the license is in effect, and
         HARVARD shall cooperate fully with LICENSEE in connection with any such
         registration or recordation.

11.8     Any notices to be given hereunder shall be sufficient if signed by the
         party (or party's attorney) giving same and either: (i) delivered in
         person; (ii) mailed certified mail return receipt requested; or (iii)
         faxed to other party if the sender has evidence of successful
         transmission and if the sender promptly sends the original by ordinary
         mail, in any event to the following addresses:

         If to LICENSEE:
           NanoSys, Inc.
           2625 Hanover Street
           Palo Alto, CA 94304
           Attn: Lawrence A. Bock
           Fax: 650-745-1273

         cc:      Wilson, Sonsini, Goodrich & Rosati
                  650 Page Mill Road
                  Palo Alto, California 94304
                  Attn: Michael J. O'Donnell, Esq.
                  Fax: 650/493-6811

         If to HARVARD:
                  Office for Technology and Trademark Licensing
                  Harvard University
                  Holyoke Center, Suite 727
                  1350 Massachusetts Avenue
                  Cambridge, MA 02138
                  Fax: (617) 495-9568

         By such notice either party may change their address for future
         notices.

                                                                              23

<PAGE>

         Notices delivered in person shall be deemed given on the date
         delivered. Notices sent by fax shall be deemed given on the date faxed.
         Notices mailed shall be deemed given on the date postmarked on the
         envelope.

11.9     Should a court of competent jurisdiction later hold any provision of
         this Agreement to be invalid, illegal, or unenforceable, and such
         holding is not reversed on appeal, it shall be considered severed from
         this Agreement. All other provisions, rights and obligations shall
         continue without regard to the severed provision, provided that the
         remaining provisions of this Agreement are in accordance with the
         intention of the parties.

11.10    In the event of any controversy or claim arising out of or relating to
         any provision of this Agreement or the breach thereof, the parties
         shall try to settle such conflict amicably between themselves. Subject
         to the limitation stated in the final sentence of this Section, any
         such conflict which the parties are unable to resolve promptly shall be
         settled through arbitration conducted in accordance with the rules of
         the American Arbitration Association. The demand for arbitration shall
         be filed within a reasonable time after the controversy or claim has
         arisen, and in no event after the date upon which institution of legal
         proceedings based on such controversy or claim would be barred by the
         applicable statute of limitation. Such arbitration shall be held in
         Boston, Massachusetts. The award through arbitration shall be final and
         binding. Either party may enter any such award in a court having
         jurisdiction or may make application to such court for judicial
         acceptance of the award and an order of enforcement, as the case may
         be. Notwithstanding the foregoing, either party may, without recourse
         to arbitration, assert against the other party a third-party claim or
         cross-claim in any action brought by a third party, to which the
         subject matter of this Agreement may be relevant.

11.11    This Agreement constitutes the entire understanding between the parties
         and neither party shall be obligated by any condition or representation
         other than those expressly stated herein or as may be subsequently
         agreed to by the parties hereto in writing.

11.12    Nothing in this Agreement shall be deemed to prevent LICENSEE from
         commercializing products similar to or competitive with a LICENSED
         PRODUCT, so long as LICENSEE complies with its obligations under this
         Agreement.

11.13    The relationship between HARVARD and LICENSEE established by this
         Agreement is that of independent contractors. Nothing in this Agreement
         shall be construed to create any other relationship between HARVARD and
         LICENSEE. Neither party shall have any right, power or authority to
         assume, create or incur any expense, liability or obligation, express
         or implied, on behalf of the other.

11.14    In the event either party hereto is prevented from or delayed in the
         performance of any of its obligations hereunder by reason of acts of
         God, war, strikes, riots, storms, fires or any other cause whatsoever
         beyond the reasonable control of the party, the party so prevented or
         delayed shall be excused from the performance of any such obligation to
         the extent and during the period of such prevention or delay.

                                                                              24

<PAGE>

11.15    NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY
         FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES
         (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE
         SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH
         CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE,
         EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE
         POSSIBILITY OR LIKELIHOOD OF SAME. For the avoidance of doubt, the
         parties acknowledge that the foregoing limitation of liability is not
         intended to apply to any of the following damages of HARVARD (and
         accordingly such damages shall be recoverable by HARVARD to the same
         extent they would be in the absence of that limitation): (i) amounts
         owed to HARVARD pursuant to the terms of this Agreement; (ii) amounts
         covered by LICENSEE's indemnity of Section 11.2; (iii) damages for
         infringement or violation of any patent, copyright, trademark, or other
         intellectual property right of HARVARD; and (iv) damages arising from
         the willful misconduct of LICENSEE.

11.16    HARVARD'S AGGREGATE LIABILITY FOR ALL DAMAGES OF ANY KIND RELATING TO
         THIS AGREEMENT OR ITS SUBJECT MATTER (WHETHER SUCH DAMAGES ARE BASED ON
         CONTRACT, TORT, INCLUDING NEGLIGENCE, OR OTHERWISE) SHALL NOT EXCEED
         THE AMOUNT PAID BY LICENSEE TO HARVARD UNDER THIS AGREEMENT.

11.17    This Agreement may be executed in counterparts, each of which shall be
         deemed an original, but both of which together shall constitute one and
         the same instrument.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
         executed by their duly authorized representatives.

         PRESIDENT AND FELLOWS                                NANOSYS, INC

           OF HARVARD COLLEGE

          /s/  Joyce Brinton                             /s/ Calvin Chow
         ------------------------------------------      -----------------------
         Joyce Brinton, Director                               Signature
         Office for Technology and Trademark Licensing

                                                         Calvin Chow
                                                         -----------------------
                                                                  Name

                  4/15/03                                Chief Operating Officer
         ------------------------------                  -----------------------
                   Date                                          Title

                                                                4-25-03
                                                         -----------------------
                                                                  Date

                                                                              25

<PAGE>

                                   APPENDIX A

The following comprise PATENT RIGHTS:

US Patent Applications 10/152,490, filed 5/20/02 and 10/196,337 filed 7/16/02, a
PCT application, PCT/US02/16133 filed 5/20/02 all entitled Nanoscale Wires and
Related Devices, Harvard Case #2058

                                                                              26

<PAGE>

                                   APPENDIX B

<TABLE>
<CAPTION>
CASE       LEAD INVENTOR                    TITLE                           AGENCY                    GRANT NUMBERS
---------------------------------------------------------------------------------------------------------------------
<S>       <C>               <C>                                       <C>                            <C>
2058      Lieber,Charles    Design and Hierarchical Assembly of       Office of Naval Research       N00014-01-1-0651
                            Nanotube-Based Moletronics
2058      Lieber,Charles    Nanostructured Functional and             Office of Naval Research       N00014-00-1-0476
                            Multifunctional Materials
2058      Lieber,Charles    Carbon Nanotube Molecular Electronics     Office of Naval Research       N00014-99-1-0495
2058      Lieber,Charles    Nanowire Thermoelectrics                  Office of Naval Research       N00014-98-1-0499
2058      Lieber,Charles    Organized Nanorod-Superconductor          Office of Naval Research       N00014-94-1-0302
                            Composites
</TABLE>

                                                                              27

<PAGE>
                                   APPENDIX C

            Exclusive License of Harvard Case 2058 to Nano Sys, Inc.

                                   ASSIGNMENT

         THIS ASSIGNMENT is made effective on 1st day of January, 2003 between:

         (1)      University of Southampton of University Road, Highfield,
Southampton 5017 IBJ, a legal body organised under the laws of England
(hereinafter the "Assignor") and

         (2)      PRESIDENT AND FELLOWS OF HARVARD COLLEGE, a nonprofit
Massachusetts educational corporation having offices at the Office for
Technology and Trademark Licensing, Holyoke Center, Suite 727,1350 Massachusetts
Avenue, Cambridge, Massachusetts 02138 (hereinafter the "Assignee").

         WHEREAS:

         (A)      The Assignor has ownership rights in the invention of U.S.
Patent Application serial number 10/152,490, and corresponding International
Patent Application Serial No. PCT/US02/16133, both entitled "Nanoscale Wires and
Related Devices", both filed May 21, 2002, which carry the internal Assignee
case number designation of 2058 and the internal Assignor case number
designation of 2519 (hereinafter "the Patent Applications"), by virtue of the
contract of employment of David C. Smith with the Assignor; and

         (B)      The Assignor wishes to assign its ownership rights in the
invention including the Patent Applications to the Assignee.

         NOW THIS ASSIGNMENT WITNESSETH:

         In consideration of the sum of one pound sterling and other good and
valuable consideration the receipt of which the Assignor hereby acknowledges the
Assignor
<PAGE>

hereby assigns and conveys unto the Assignee absolutely the invention and the
Patent Applications thereto together with all right, title and interest in and
to said applications and in and to any continuations, divisionals,
continuation-in-part patent applications (to the extent a person under an
obligation to assign patent rights to the Assignee and David C. Smith are both
properly named inventors, based on U.S. patent law) and patents which issue on
said applications including patents of reissue or re-examination, worldwide,
together with all rights of action powers and benefits belonging or accrued to
the same including the right to claim priority under the Paris Convention.

         IN WITNESS WHEREOF the parties have executed and delivered these
presents in the United Kingdom:

EXECUTED by The University of Southampton.

in accordance with its charter of incorporation:

/s/ Dr. Peter Hooper                                    19, Dec. 2002
--------------------                          ----------------------------------
Dr. Peter Hooper                                            Date
Deputy Director, Centre for Enterprise and Innovation

EXECUTED by the PRESIDENT AND FELLOWS OF HARVARD COLLEGE.
in accordance with the laws of its incorporation:

/s/ Joyce Brinton                                          1/6/03
-----------------------                       ----------------------------------
Joyce Brinton                                               Date
Director of the Office for Technology and Trademark Licensing
Harvard University<PAGE>

                                                                    EXHIBIT 10.8

                                LICENSE AGREEMENT

                                       FOR

                             NANOCRYSTAL TECHNOLOGY

                                    BETWEEN

                                 NANOSYS, INC.

                                       AND

                  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

                                   THROUGH THE

                             ERNEST ORLANDO LAWRENCE
                          BERKELEY NATIONAL LABORATORY

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<S>                                                                                 <C>
1.    Background.............................................................        1
2.    Definitions............................................................        1
3.    License Grant..........................................................        3
4.    License Issue Fee......................................................        4
5.    Milestone Fee..........................................................        4
6.    Royalties and Payments.................................................        4
7.    Performance Requirements...............................................        6
8.    Progress and Royalty Reports...........................................        7
9.    Books and Records......................................................        8
10.   Life of the Agreement..................................................        8
11.   Termination by Berkeley Lab............................................        9
12.   Termination by Licensee................................................        9
13.   Disposition of Licensed Products upon Termination......................        9
14.   Use Of Names and Nondisclosure of Agreement............................        9
15.   Limited Warranty.......................................................       10
16.   Patenting and foreign rights...........................................       11
17.   Patent Infringement....................................................       12
18.   Waiver.................................................................       12
19.   Assignment.............................................................       13
20.   Indemnification........................................................       13
21.   Late Payments..........................................................       14
22.   Notices................................................................       14
23.   U.S. Manufacture.......................................................       15
24.   Patent Marking.........................................................       15
25.   Government Approval or Registration....................................       15
26.   Export Control Laws....................................................       15
27.   Force Majeure..........................................................       15
28.   Miscellaneous..........................................................       15

Exhibit 1 Licensed (Exclusive) Patents.......................................       17
Exhibit 2 Licensed (FOU Exclusive) Patents...................................       18
</TABLE>

<PAGE>

                              LICENSE AGREEMENT FOR
                             NANOCRYSTAL TECHNOLOGY

This license agreement (the "Agreement") is entered into by The Regents of the
University of California, Department of Energy contract-operators of the Ernest
Orlando Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA
94720, ("Berkeley Lab"), and Nanosys, Inc., a Delaware corporation ("Licensee")
having its principal place of business at 2625 Hanover St., Palo Alto, CA 94304.

                                  1. BACKGROUND

1.1.     Certain inventions, generally characterized as nanocrystals and related
         technology and covered by the Berkeley Lab cases listed herein, (the
         "Invention"), were made in the course of research at Berkeley Lab by
         Dr. Paul Alivisatos and colleagues under Berkeley Lab's contract with
         the United States Department of Energy ("DOE").

1.2.     As DOE sponsored development of the Invention, this Agreement and the
         resulting license are subject to overriding obligations to the federal
         government pursuant to the provisions of the applicable law or
         regulations.

1.3.     Berkeley Lab wants the Invention developed and used to the fullest
         extent so that the general public enjoys the benefits of the
         government-sponsored research.

1.4.     Licensee wants to obtain certain rights from Berkeley Lab for the
         commercial development, manufacture, use, and sale of the Invention.

1.5.     Licensee is a "small business concern" as defined at Section 2 of
         Public Law 85-536 (15 U.S.C. 632).

Therefore the parties agree as follows:

                                 2. DEFINITIONS

2.1.     "Effective Date" means November 9, 2002.

2.2.     "Field of Use" means all uses of the Licensed Patents, except the
         following, which are specifically excluded: the use of the Licensed
         Patents for [*** Redacted], [*** Redacted], [*** Redacted] and [***
         Redacted] for plant, animal, and human [*** Redacted] including,
         without limitation, [*** Redacted], [*** Redacted]. Licensee
         acknowledges that a third party has rights encompassing the exclusions
         to the Field of Use and in no event may a Field of Use under Licensed
         (FOU Exclusive) Patents be construed as covering the excluded fields.

2.3.     "Highly Inflationary Currency" means the currency of any economy with a
         cumulative inflation rate of 100% or more over the most recent three
         calendar years, as measured by consumer price indices published by the
         International Monetary Fund (International Financial Statistics),
         Washington, D.C.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                    1 of 19
<PAGE>

2.4.     "Licensed (Exclusive) Patents" means Berkeley Lab's interest in any
         subject matter claimed in or covered by any of the patents or patent
         applications listed in Exhibit 1.

2.5.     "Licensed (FOU Exclusive) Patents" means Berkeley Lab's interest in any
         subject matter claimed in or covered by any of the patents or patent
         applications listed in Exhibit 2.

2.6.     "Licensed Patents" means Berkeley Lab's interest in any subject matter
         claimed in or covered by any of the patents or patent applications
         listed in Exhibits 1 or Exhibit 2, and any additional corresponding
         foreign patent application or patent for which Licensee has met the
         requirements of paragraph 16.4; any division, reexamination,
         continuation, continuation-in-part (excluding new matter contained and
         claimed in that continuation-in-part), or other application that is a
         successor to any of the foregoing applications; any patents issuing on
         any of the foregoing; and all renewals, reissues and extensions
         thereof.

2.7.     "Licensed Product" means any product, service or process that employs
         or is produced by the practice of any invention claimed in any of
         Licensed Patents or whose manufacture, use, practice, sale, offer for
         sale, or importation would constitute, but for the license Berkeley Lab
         grants to Licensee under this Agreement, an infringement of any Valid
         Claim in Licensed Patents.

2.8.     "Selling Price" for the purpose of computing royalties means the price
         at which Licensee or its sublicensee sells a Licensed Product in an
         arms-length transaction. When a Licensed Product is not sold, but is
         otherwise disposed of, the Selling Price of that Licensed Product for
         the purpose of computing royalties is the selling price at which
         products of similar kind and quality, sold in similar quantities, are
         [*** Redacted]. When such products are not [*** Redacted], the Selling
         Price of a Licensed Product otherwise transferred, for the purpose of
         computing royalties, is the [*** Redacted] at which products of similar
         kind and quality, sold in similar quantities, are then currently being
         offered for sale [*** Redacted]. When such products are not currently
         sold or offered for sale by Licensee or others, then the Selling Price,
         for the purpose of computing royalties, shall be negotiated by the
         parties in good faith based on the [*** Redacted].

2.9.     "Sublicensing Income" means amounts received by Licensee from a
         non-affiliate third party in consideration for the right to make,
         use, offer for sale, sell, or import Licensed Products, including
         without limitation amounts received by way of license issue fees,
         milestone payments, minimum annual royalties and royalties on the sale
         or distribution of such Licensed Products. Notwithstanding the
         foregoing, Sublicensing Income shall not include the following:

         2.9.1.   income received by Licensee as reimbursement for Licensee's
                  actual and reasonable [*** Redacted] as set forth in a written
                  [*** Redacted] agreement between Licensee and its sublicensee;
                  amounts received for services or products (provided, however,
                  that Licensee sales of Licensed Product to a sublicensee is
                  subject to the royalty provision of paragraph 6.1);

         2.9.2.   the fair market value of sales of [*** Redacted] sold by
                  Licensee to a sublicensee;

         2.9.3.   amounts in consideration for [*** Redacted] or other
                  [*** Redacted] other than that covered in the [*** Redacted];
                  or

         2.9.4    amounts in consideration for the sale of all or [*** Redacted]
                  or otherwise.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                    2 of 19

<PAGE>

2.10.    "Valid Claim" means a claim within (a) an issued, unexpired patent that
         Berkeley Lab has not disclaimed or otherwise admitted to the relevant
         patent office or court to be invalid or otherwise unenforceable, and
         has not been held invalid by a court of competent jurisdiction from
         which no appeal has been or can be taken or (b) a patent application
         that has not been pending more than 5 years, provided that Berkeley Lab
         is pursuing such claim in a good faith belief in its patentability and
         enforceability upon issuance of a patent containing such claim.

                                3. LICENSE GRANT

3.1.     Subject to the limitations set forth in this Agreement, Berkeley Lab
         grants to Licensee nontransferable, royalty-bearing licenses, under
         Licensed Patents to make, have made, use, offer for sale, sell, and
         import Licensed Products as follows:

         3.1.1.   limited exclusive for Licensed (Exclusive) Patents; and

         3.1.2.   limited exclusive and solely within the Field of Use for
                  Licensed (FOU Exclusive) Patents.

3.2.     Any license under this Agreement is subject to the following: (a) DOE's
         royalty-free license for federal government purposes only, and (b)
         DOE's option to grant licenses either if reasonable steps to
         commercialize the Invention are not carried out or in order to meet
         federal regulations.

3.3.     Berkeley Lab also grants to Licensee the right to issue, royalty-
         bearing sublicenses only in the Field of Use to make, have made,
         use, offer for sale, sell, and import Licensed Products, so long as
         Licensee has current exclusive rights in the Field of Use for all
         Licensed Patents covered by the sublicense.

3.4.     Any sublicense Licensee grants must be consistent with all the rights
         and obligations due Berkeley Lab and the United States Government under
         this Agreement, including, without limitation, the license back to the
         United States Government.

3.5.     Licensee shall provide Berkeley Lab with a copy of each sublicense
         issued under this Agreement; collect payment of all royalties and
         payments due Berkeley Lab from sublicenses; and summarize and deliver
         all reports due Berkeley Lab from sublicenses under Article 8 (PROGRESS
         AND ROYALTY REPORTS). Sublicenses provided to Berkeley Lab under this
         section may be provided in redacted form, provided that such redacted
         sublicenses contain all terms necessary for Berkeley Lab to determine
         Licensee's compliance with the obligations of this Agreement; and
         provided further that upon request, Berkeley Lab's representatives can
         review the sublicenses in their entirety at Licensee's facility.

3.6.     If this Agreement terminates for any reason, Licensee will assign to
         Berkeley Lab, and Berkeley Lab will honor any sublicenses granted
         hereunder, to the extent that Berkeley Lab's duties under such
         sublicenses are no greater than those arising under this Agreement.

3.7.     Berkeley Lab expressly reserves the right to use the Invention and
         associated technology for educational and research purposes.

                                    3 of 19
<PAGE>

                              4. LICENSE ISSUE FEE

4.1.     Licensee shall pay Berkeley Lab a license issue fee of [*** Redacted].
         This license issue fee accrues on the Effective Date, and Licensee
         shall pay [*** Redacted] of this fee within 30 days of the Effective
         Date and [*** Redacted] within twelve months of the Effective Date.

4.2.     This fee is [*** Redacted] and is [*** Redacted].

                              5. MILESTONE FEE

5.1.     Following an initial public offering or series of public offerings of
         Licensee securities which raises in the aggregate at least $5 million
         or sale of all or substantially all of the assets or equity of Licensee
         in a transaction(s) worth at least $5 million ("Offering"), Licensee
         shall pay to Berkeley Lab the equivalent of the price at the Offering
         of 60,000 shares of Licensee's common stock. Such payments shall be
         made in installments with one-third payable 9 months from the Offering,
         one-third payable 18 months from the Offering and one-third payable 26
         months from the Offering. Such payments shall include interest from the
         date of the Offering to the date such payment is made. Interest shall
         be compounded on the date such payment is made, and shall be charged
         at the prime lending rate as published in the Wall Street Journal on
         the date such payment is made. Licensee shall adjust the 60,000 shares
         to take into account any stock splits or reverse stock splits since the
         Effective Date.

                              6. ROYALTIES AND PAYMENTS

6.1.     Licensee shall pay to Berkeley Lab an earned royalty of [*** Redacted]%
         of the Selling Price of each Licensed Product. In no event shall
         more than one royalty apply to the sale of any given Licensed Product,
         regardless of the number of Licensed Patents embodied therein.

6.2.     Under this Agreement a Licensed Product is considered as sold when
         invoiced, or if not invoiced, when delivered to a third party. But when
         the last patent covering a Licensed Product expires or when the license
         terminates, any shipment made on or before the day of that expiration
         or termination that has not been billed out before is considered as
         sold (and therefore subject to royalty). Berkeley Lab shall credit
         royalties that Licensee pays on a Licensed Product that the customer
         does not accept.

6.3.     If a Licensed Product is sold as a combination product containing both
         the Licensed Product and one or more other components that Licensee
         customarily sells separately, Selling Price is calculated by
         multiplying the [*** Redacted] by the fraction [*** Redacted]
         where A is the [*** Redacted] of the Licensed Product sold separately
         by Licensee and B is the [*** Redacted] of the combination products
         sold separately by Licensee during the relevant royalty payment period.

6.4.     If Licensee obtains a license from a third party(s) to a patent that
         must otherwise be infringed by Licensee in order to make the Licensed
         Products (" Third Party Patent") then Licensee may reduce the
         [*** Redacted] royalty rate specified in paragraph 6.1 by an amount
         equal to [*** Redacted] of the royalty Licensee pays the licensor of
         such Third Party Patent, provided, however, in no case shall the
         royalty rate paid to Berkeley Lab for Licensed Products be less than
         [*** Redacted].

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                    4 of 19
<PAGE>
6.5.     For each sublicense, Licensee shall pay Berkeley Lab [*** Redacted]%
         of Sublicensing Income. If Sublicensing Income arises under an
         agreement in which both a Licensed Patent and one or more other patent,
         patent application or copyrighted software program are licensed to a
         third party by the Licensee, then the Licensee shall in good faith
         allocate its total compensation under such agreement to either the
         Licensed Patents or the other patent, patent application or copyrighted
         software, and such portion allocated to the Licensed Patent(s) shall
         constitute the Sublicensing Income; provided, however, that Licensee
         shall (i) promptly notify Berkeley Lab of any such agreement for which
         it intends to apportion the income; (ii) provide Berkeley Lab with a
         copy of that agreement (if it has not already done so pursuant to
         paragraph 3.5) together with a written report explaining its
         apportionment for the Sublicensing Income; (iii) consider and respond
         in good faith to Berkeley Lab's comments on the apportionment; and (iv)
         pay Berkeley Lab no less than [*** Redacted]% of the total amounts
         received by Licensee from the third party in consideration for a
         sublicense for Licensed Patents.

6.6.     Licensee shall pay to Berkeley Lab by August 31 of each year the
         difference between the earned royalties for that calendar year Licensee
         has already paid to Berkeley Lab and the minimum annual royalty set
         forth in the following schedule. Berkeley Lab shall credit that minimum
         annual royalty paid against the earned royalty due and owing for the
         calendar year in which Licensee made the minimum payment.

<TABLE>
<CAPTION>
Calendar Year                      Minimum Annual Royalty
-------------                      ----------------------
<S>                                <C>
2002                                      $ [*** Redacted]
2003                                      $ [*** Redacted]
2004                                      $ [*** Redacted]
2005                                      $ [*** Redacted]
2006                                      $ [*** Redacted]
2007                                      $ [*** Redacted]
2008                                      $ [*** Redacted]
2009 and each year thereafter             $ [*** Redacted]
</TABLE>

6.7.     Licensee shall send payment for royalties accruing to Berkeley Lab
         quarterly together with its royalty report under paragraph 8.3.

6.8.     Licensee shall make checks payable to "The Regents of the University of
         California (Berkeley Lab/L-02-1364)." Licensee shall pay Berkeley Lab
         only in United States dollars. If a Licensed Product is sold for
         currency other than United States dollars (not including Highly
         Inflationary Currency), Licensee shall first determine the earned
         royalties in the foreign currency of the country in which the
         Licensed Product was sold and then convert them into equivalent United
         States dollars at the closing exchange rate published by The Wall
         Street Journal on the last business day of the reporting period. If a
         Licensed Product is sold for a Highly Inflationary Currency, Licensee
         shall convert the sales subject to royalties into equivalent United
         States funds using the closing exchange rates in effect on the date of
         invoicing (or if no invoicing, of delivery) as published by The Wall
         Street Journal. Licensee shall quote the exchange rate in the
         Continental method (local currency per U.S. dollar).

6.9.     Licensee may not reduce royalties payable by any taxes, fees, other
         charges imposed on the remittance of royalty income. Licensee is also
         responsible for all bank transfer charges.

6.10.    If Licensee cannot promptly remit any royalties for sales in any
         country where a Licensed Product is sold because of legal restrictions,
         upon notice to Berkeley Lab, Licensee may deposit in United States
         funds royalties due Berkeley Lab to Berkely Lab's account in a bank or
         other depository in that country. If Licensee is not permitted to
         deposit those payments

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                    5 of 19
<PAGE>

         in U.S. funds under the laws of that country, Licensee may deposit
         those payments in the local currency to Berkeley Lab's account in a
         bank or other depository in that country.

6.11.    If a court of competent jurisdiction and last resort holds invalid any
         patent or any of the patent claims within Licensed Patent in a final
         decision from which no appeal has or can be taken, Licensee's
         obligation to pay royalties based on that patent or claim will cease as
         of the date of that final decision. Licensee, however, shall pay any
         royalties that accrued before that decision or that are based on
         another patent or claim not involved in that decision.

6.12.    Licensee has no duty to pay Berkeley Lab royalties under this Agreement
         on a Licensed Product Licensee sells to the United States Government
         including any United States Government agency. Licensee shall reduce
         the amount charged for a Licensed Product sold to the United States
         Government by an amount equal to the royalty otherwise due Berkeley
         Lab.

                          7. PERFORMANCE REQUIREMENTS

7.1.     Licensee shall diligently proceed with the development, manufacture and
         sale of Licensed Products and shall diligently endeavor to market them
         within a reasonable time after the Effective Date in quantities
         sufficient to meet the market demand.

7.2.     Licensee shall make best efforts to obtain all necessary governmental
         approvals for the manufacture, use and sale of Licensed Products.

7.3.     Licensee is entitled to exercise prudent and reasonable business
         judgment in meeting its performance requirements under this Agreement.

7.4.     If Licensee is unable to perform any of the following, then Berkeley
         Lab may either terminate this Agreement or reduce a limited exclusive
         license to a nonexclusive license.

         7.4.1.   by 18 months from the Effective Date, develop a process for
                  the synthesis of nanodots and/or nanorods for prototype
                  development; such [*** Redacted] must be at research
                  quantities sufficient for prototype development of the
                  Licensed Product(s) specified in the Licensee's progress
                  reports submitted pursuant to paragraph 8.1, with [***
                  Redacted], yielding material with [*** Redacted] and [***
                  Redacted] of [*** Redacted];

         7.4.2.   by 18 months from the Effective Date, develop application
                  specific [*** Redacted] procedures for these materials,
                  including [*** Redacted] with [*** Redacted], [*** Redacted],
                  and [*** Redacted] and [*** Redacted];

         7.4.3.   by 24 months from the Effective Date, develop [*** Redacted],
                  which includes at least [*** Redacted], or equivalent, e.g.,
                  [*** Redacted], [*** Redacted] etc., of [*** Redacted]
                  containing [*** Redacted] and/or [*** Redacted] with [***
                  Redacted] and [*** Redacted] and [*** Redacted];

         7.4.4.   by 30 months from the Effective Date, perform and deliver to
                  Berkeley Lab a market assessment of major benefits of Licensed
                  Product materials versus existing commercial approaches;

         7.4.5.   by 30 months from the Effective Date, develop a [*** Redacted]
                  for either [*** Redacted] or [*** Redacted] of amounts of
                  nanorods and/or nanodots that are consistent with the Licensed
                  Products identified as initial products by the market
                  assessment provided under paragraph 7.4.4;

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                    6 of 19
<PAGE>

         7.4.6.   by 36 months from the Effective Date, develop initial
                  prototypes demonstrating commercially useful functionality of
                  nanorods and/or nanodots in Licensed Products, for example,
                  [*** Redacted] and [*** Redacted] and related devices; for
                  [*** Redacted], prototype devices with [*** Redacted] with
                  [*** Redacted]; for [*** Redacted], [*** Redacted];

         7.4.7.   by 36 months from the Effective Date, develop and provide
                  to Berkeley Lab a technical and commercialization plan for
                  applications in [*** Redacted], for example, [*** Redacted]
                  and [*** Redacted];

         7.4.8.   by 48 months from the Effective Date, enter into a letter
                  of intent or other contract with an appropriate
                  commercialization partner for Licensed Products;

         7.4.9.   by 56 months from the Effective Date, make commercial
                  sales of Licensed Product; or

         7.4.10.  at any time during the exclusive period of this Agreement,
                  reasonably fill the market demand for Licensed Products
                  following commencement of commercial sales

7.5.     Prior to termination of this Agreement or reduction of a limited
         exclusive license to a nonexclusive license for failure to meet any of
         the performance requirements set forth in paragraphs 7.4.1-7.4.10, or
         as mutually agreed upon, Licensee and Berkeley Lab shall meet within
         30 days of Licensee's request to discuss Licensee's past and planned
         efforts to meet such performance requirements. That meeting shall take
         place at Berkeley Lab or other mutually agreed location, and shall only
         be required if Licensee makes that request within 21 days of Berkeley
         Lab's notice of termination or reduction to nonexclusive license. To
         the extent that Licensee demonstrates it has made reasonable efforts to
         meet such performance requirements, and by mutual written consent, the
         parties shall amend or extend the requirements of paragraphs 7.4.1
         -7.4.10 at the written request of Licensee in response to legitimate
         business or technical reasons.

                         8. PROGRESS AND ROYALTY REPORTS

8.1.     Beginning May 31, 2003 and semiannually thereafter, Licensee shall
         submit to Berkley Lab a progress report covering Licensee's activities
         related to the development and testing of all Licensed Products and the
         obtaining of the governmental approvals necessary for marketing.
         Licensee shall make these progress reports until commercial sales of
         the Licensed Product start.

8.2.     The progress reports Licensee submits under paragraph 8.1 must include,
         but not be limited to, the following topics:

         8.2.1.   summary of work completed related to the requirements of
                  paragraph 7.4;

         8.2.2.   key scientific discoveries;

         8.2.3.   summary of work in progress;

         8.2.4.   current schedule of anticipated milestones; and

         8.2.5.   market plans for introduction of Licensed Products; and

         8.2.6.   number of full-time equivalent employees or agents (FTEs)
                  working on the development of Licensed Products and overall
                  number of FTEs employed by Licensee.

8.3.     Upon the earlier of four years after the Effective Date or after
         the first commercial sale of a Licensed Product anywhere in the world,
         Licensee shall make quarterly royalty reports to Berkeley Lab on
         or before February 28, May 31, August 31 and November 30 of each year.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                    7 of 19
<PAGE>
         Each royalty report must cover the most recently completed
         calendar quarter and must show for all sales (or other transfer in
         accordance with paragraph 2.8):

         8.3.1.   the Selling Price of each type of Licensed Product sold by
                  Licensee;

         8.3.2.   the number of each type of Licensed Product sold;

         8.3.3.   the royalties, in U.S. dollars, payable under this
                  Agreement on those sales;

         8.3.4.   the exchange rates used in calculating the royalty due;

         8.3.5.   the royalties on government sales that otherwise would have
                  been due under paragraph 6.12; and

         8.3.5.   for each sublicense, if any:

                  (1)      the sublicensee;

                  (2)      the information set forth in paragraphs 8.3.1 to
                           8.3.5 for that sublicensee's sales or other
                           disposition of Licensed Product.

8.4.     If no sales of Licensed Products have been made during any required
         reporting period, Licensee shall make a statement to this effect.

                              9. BOOKS AND RECORDS

9.1.     Licensee shall keep books and records accurately showing all Licensed
         Products manufactured, used, sold, imported or otherwise disposed of
         under the terms of this Agreement. Licensee shall preserve those books
         and records for at least five years, from the date of the royalty
         payment to which they pertain and shall open them to inspection by
         representatives or agents of Berkeley Lab at reasonable times.

9.2.     Berkeley Lab shall bear the fees and expenses of Berkeley Lab's
         representatives performing the examination of the books and records.
         But if the representatives discover an error in underpaying royalties
         to Berkeley Lab of more than 5% of the total royalties due for any
         year, then Licensee shall bear the fees and expenses of these
         representatives and the difference between the earned royalties and the
         reported royalties (which shall be subject to the provisions of Article
         21 (LATE PAYMENTS)).

                            10. LIFE OF THE AGREEMENT

10.1.    Unless otherwise terminated by operation of law or by acts of the
         parties in accordance with the terms of this Agreement, this Agreement
         is in force from the Effective Date and expires concurrently with the
         last-to-expire issued Licensed Patent.

10.2.    Any termination of this Agreement shall not affect the rights and
         obligations set forth in the following Articles:

         Article 9         Books and Records

         Article 13        Disposition of Licensed Products on Hand upon
                           Termination

         Article 14        Use of Names and Trademarks and Confidentiality

         Article 15        Limited Warranty

         Article 20        Indemnification

         Article 26        Export Control Laws

                                     8 of 19
<PAGE>

10.3.    Termination does not affect in any manner any rights of Berkeley Lab
         arising under this Agreement before the termination.

                         11. TERMINATION BY BERKELEY LAB

11.1.    Subject to paragraph 7.5, if Licensee violates or fails to perform any
         material term of this Agreement, then Berkeley Lab may give written
         notice of such default ("Default Notice") to Licensee. If Licensee
         fails to cure that default and provide Berkeley Lab with reasonable
         evidence of the cure within 60 days of the Default Notice, Berkeley Lab
         may terminate this Agreement and the licenses granted by a second
         written notice ("Termination Notice") to Licensee. If Berkeley Lab
         sends a Termination Notice to Licensee, this Agreement automatically
         terminates on the effective date of the Termination Notice.

                           12. TERMINATION BY LICENSEE

12.1.    Licensee at any time may terminate this Agreement in whole or as to any
         portion of Licensed Patents by giving written notice to Berkeley Lab.
         Licensee's termination notice must indicate whether Licensee has any
         inventory of Licensed Products. Licensee's termination of this
         Agreement will be effective 90 days after its notice.

              13. DISPOSITION OF LICENSED PRODUCTS UPON TERMINATION

13.1.    Within 45 days of termination of this Agreement for any reason,
         Licensee shall provide Berkeley Lab with a written inventory of all
         Licensed Products in process of manufacture or in stock. Licensee shall
         dispose of those Licensed Products within 20 days of termination. The
         sale of any Licensed Product within the 20 days is subject to the terms
         of this Agreement.

                      14. USE OF NAMES AND CONFIDENTIALITY

14.1.    In accordance with California Education Code Section 92000, Licensee
         shall not use in advertising, publicity or other promotional activities
         any name, trade name, trademark, or other designation of the University
         of California, nor shall Licensee so use "Ernest Orlando Lawrence
         Berkeley National Laboratory" or "Department of Energy" (including any
         contraction, abbreviation, or simulation of any of the foregoing)
         without Berkeley Lab's prior written consent.

14.2.    Neither party may disclose the terms of this Agreement to a third party
         without express written permission of the other party, except when
         required under either the California Public Records Act or other
         applicable law or court order. Notwithstanding the foregoing,
         disclosures of the terms of this Agreement are permitted as follows:

         14.2.1.  as necessary for Licensee to secure financing through private
                  markets, engage in corporate partnership discussions, or
                  comply with applicable accounting requirements, or securities
                  laws or regulations, Licensee may disclose the terms of this
                  Agreement under a written confidentiality agreement with terms
                  as protective as those of this Article 14;

         14.2.2.  as necessary for Licensee to publicly disclose terms of this
                  Agreement in conjunction with a public financing or to comply
                  with applicable securities laws or regula-

                                    9 of 19
<PAGE>

                  tions, after Licensee has provided Berkeley Lab with notice of
                  such disclosure with sufficient opportunity to seek redaction
                  of certain terms of the Agreement; and

         14.2.3.  Berkeley Lab may disclose the existence of this Agreement and
                  the extent of the grant in Article 3 (License Grant), but
                  shall not otherwise disclose the terms of this Agreement,
                  except to the DOE.

14.3     All information provided to Berkeley Lab by Licensee under this
         agreement, including but not limited to information listed in Section
         7.4 of this Agreement, e.g., sublicense agreements, technical reports,
         development plans, marketing evaluations and reports, and royalty
         reports, is deemed to be Confidential Information.

         14.3.1   Berkeley Lab will maintain the confidentiality of the
                  Confidential Information and will not disclose the
                  Confidential Information to any third party, and will not use
                  the Confidential Information for any purpose other than as
                  necessary to administer this Agreement.

         14.3.2   The obligations of Berkeley Lab with respect to Confidential
                  Information will not apply to information disclosed under this
                  agreement to the extent such information:

         (a)      is generally known to the public at the time of disclosure or
                  becomes generally known through no wrongful act on the part of
                  Berkeley Lab;

         (b)      is in Berkeley Lab's possession at the time of disclosure
                  other than as a result of prior disclosure by Licensee or a
                  breach of any legal obligation by Berkeley Lab or a third
                  party;

         (c)      becomes known to Berkeley Lab through disclosure by sources
                  other than Licensee having no duty of confidentiality to
                  Licensee, whether direct or indirect, with respect to such
                  information and having the legal right to disclose such
                  information;

         (d)      is independently developed by Berkeley Lab without reference
                  to or reliance upon the information as can be documented by
                  written records; or

         (e)      is required to be disclosed by Berkeley Lab to comply with
                  applicable laws or governmental regulations, provided that the
                  Berkeley Lab provides prior written notice of such disclosure
                  to the Licensee and takes reasonable and lawful actions to
                  avoid and/or minimize the extent of such disclosure.

         14.3.3   The provisions of this Article 14 relating to confidentiality
                  shall be in force and effect until at least 5 years following
                  the termination of this Agreement.

                              15. LIMITED WARRANTY

15.1.    Berkeley Lab warrants to Licensee that it has the lawful right to grant
         this license.

15.2.    This license and the associated Invention are provided WITHOUT WARRANTY
         OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER
         WARRANTY, EXPRESS OR IMPLIED. BERKELEY LAB MAKES NO REPRESENTATION
         OR WARRANTY THAT LICENSED PRODUCTS WILL NOT INFRINGE ANY PATENT OR
         OTHER PROPRIETARY RIGHT.

15.3.    IN NO EVENT WILL BERKELEY LAB BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR
         CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR THE
         USE OF THE INVENTION OR LICENSED PRODUCTS.

15.4.    Nothing in this Agreement may be construed as:

                                    10 of 19

<PAGE>

         15.4.1.  a warranty or representation by Berkeley Lab as to the
                  validity of Licensed Patents or scope of any of Berkeley Lab's
                  rights in Licensed Patents;

         15.4.2.  a warranty or representation that anything made, used, sold or
                  otherwise disposed of under any license granted in this
                  Agreement is or will be free from infringement of any patents
                  other than Licensed Patents;

         15.4.3.  an obligation to bring or prosecute actions or suits against
                  third parties for patent infringement, except as specifically
                  provided for in Article 17 (Patent Infringement); or

         15.4.4.  a grant by implication, estoppel or otherwise of any license
                  or rights under any patents of Berkeley Lab other than
                  Licensed Patents, regardless of whether such patents are
                  dominant or subordinate to Licensed Patents;

         15.4.5.  an obligation to furnish any know-how not provided in Licensed
                  Patents.

                        16. PATENTING AND FOREIGN RIGHTS

16.1.    Berkeley Lab shall prepare, file, prosecute and maintain patent
         applications and patents relating to inventions included in the
         Licensed Patents using patent counsel of its choice, and shall consult
         and cooperate with Licensee in connection therewith. Berkeley Lab shall
         copy Licensee promptly on all U.S.P.T.O. and foreign patent office
         actions, final drafts of proposed submissions and copies of actual
         submissions, to the extent reasonably practicable, so that Licensee
         shall be informed of the continuing prosecution, and have an
         opportunity to review and comment on such office actions and draft
         submissions. Notwithstanding the foregoing, Berkeley Lab may take any
         action useful or necessary to obtain and preserve its patent rights in
         Licensed Patents. Berkeley Lab shall use all reasonable efforts to
         amend any patent application to include claims and/or legal arguments
         reasonably requested by Licensee to protect the Licensed Products
         Licensee contemplates selling. Licensee shall keep confidential
         documents from patent offices and patent related filings and
         associated drafts.

16.2.    licensee agrees to reimburse Berkeley Lab for Berkeley Lab's
         out-of-pocket patent preparation, filing, prosecution and maintenance
         costs as follows:

         16.2.1.  100% of all such costs for Licensed (Exclusive) Patents; and

         16.2.2.  50% of all such costs for Licensed (FOU Exclusive) Patents.

16.3.    Berkeley Lab shall provide Licensee with documentation of patenting
         costs incurred when invoicing Licensee for those costs. Licensee shall
         pay Berkeley Lab within 30 days of receiving the invoice. Licensee
         shall also pay Berkeley Lab for reimbursement of such patent costs
         incurred prior to the Effective Date within 30 days of invoicing; such
         costs are estimated to be approximately [*** Redacted]. Licensee's
         obligation to reimburse patent costs continues for so long as this
         Agreement remains in effect, provided, however, that Licensee may
         terminate its obligations under this Agreement with respect to any
         given patent application or patent upon three months written notice to
         Berkeley Lab. Berkeley Lab shall use reasonable efforts to curtail
         patent costs when such a notice is received from Licensee. After such
         notice or when this Agreement terminates, Berkeley Lab may continue
         prosecution and/or maintenance of those application(s) or patent(s) at
         its sole discretion and expense; provided, however, that Licensee will
         have no further license or other right to them.

16.4.    Licensee may request that Berkeley Lab seek patent protection on the
         Licensed Patents in foreign countries if available. Berkeley Lab has no
         obligation to take action to file foreign patent applications unless
         Licensee provides written notice to Berkeley Lab at least six weeks
         before any applicable bar and that notice states which countries,
         regions or Patent

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                    11 of 19
<PAGE>

         Cooperation Treaty filing Licensee desires. If Licensee timely provides
         such notice, then Berkeley Lab shall timely make such foreign filings.
         The absence of the required notice from Licensee to Berkeley Lab acts
         as an election not to secure foreign rights.

16.5.    Berkeley Lab may file patent applications at its own expense in any
         country in which Licensee has not elected to secure patent rights.
         Those applications and resultant patents shall not be subject to this
         Agreement.

16.6.    Licensee shall promptly notify Berkeley Lab of any change in its status
         as a small business concern and of the first sublicense granted to an
         entity that does not qualify as a small business concern. A "small
         business concern" as used in this paragraph is as defined by the U.S.
         Patent and Trademark Office; currently, that is a company whose number
         of employees, including affiliates, does not exceed 500 persons (13
         C.F.R. 121.802).

                             17. PATENT INFRINGEMENT

17.1.    If Licensee learns of the substantial infringement of any of Licensed
         Patents, Licensee shall so inform Berkeley Lab in writing and shall
         provide Berkeley Lab with reasonable evidence of the infringement.
         During the period and in a jurisdiction where Licensee has exclusive
         rights under this Agreement, neither party may notify a third party of
         the infringement of any of Licensed Patents without first obtaining
         written consent of the other party, which consent shall not be
         unreasonably denied. Both parties shall use their best efforts in
         cooperation with each other to terminate such infringement without
         litigation.

17.2.    Licensee may request that Berkeley Lab take legal action against the
         infringement of Licensed (Exclusive) Patents or Licensed (FOU
         Exclusive) Patents in the Field of Use in which Licensee has current
         exclusive rights under this Agreement. Licensee shall make that request
         in writing and include reasonable evidence of the infringement and
         damages to Licensee. If the infringing activity has not been abated
         within 90 days of that request, Berkeley Lab may elect to: (a)
         commence suit on its own account; or (b) refuse to participate in the
         suit. Berkeley Lab shall give written notice of its election to
         Licensee by the end of the 90 days after receiving notice of the
         request from Licensee. Licensee may thereafter bring suit for patent
         infringement only if Berkeley Lab elects not to commence suit and if
         the infringement occurred during the period and in a jurisdiction where
         Licensee has exclusive rights under this Agreement. If, however,
         Licensee elects to bring suit in accordance with this paragraph,
         Berkeley Lab may thereafter join such suit at its own expense.

17.3.    Such legal action as is decided upon must be at the expense of the
         party on account of whom suit is brought and all consequent recoveries
         belong to that party. But if Berkeley Lab and Licensee jointly bring
         legal action and fully participate in it, the parties must jointly
         share both the expense and all recoveries in proportion to the share of
         expense each party pays.

17.4.    Each party shall cooperate with the other in litigation proceedings
         instituted under this Agreement but at the expense of the party on
         account of whom suit is brought. The party bringing the suit will
         control that litigation, except that Berkeley Lab may elect to be
         represented by counsel of its choice in any suit brought by Licensee.

                                   18. WAIVER

18.1.    The waiver of any breach of any term of this Agreement does not waive
         any other breach of that or any other term.

                                    12 of 19
<PAGE>

                                 19. ASSIGNMENT

19.1.    This Agreement is binding upon and shall inure to the benefit of
         Berkeley Lab, its successors and assigns. Upon written notice to
         Berkeley Lab, Licensee may assign this Agreement to a Licensee wholly
         owned subsidiary, or in conjunction with a sale of all or substantially
         all of the assets of Licensee. Any other attempt by Licensee to assign
         this Agreement is void unless Licensee obtains the prior written
         consent of Berkeley Lab; Berkeley Lab shall not unreasonably withhold
         that consent.

                               20. INDEMNIFICATION

20.1.    Licensee agrees to indemnify, hold harmless and defend Berkeley Lab and
         the U.S. Government and their officers, employees, and agents; the
         sponsors of the research that led to the Invention; and the inventors
         of the patents and patent applications in Licensed Patents and their
         employers against any and all claims, suits, losses, damage, costs,
         fees, and expenses resulting from or arising out of exercise of this
         license or any sublicense, except to the extent indemnification of
         Berkeley Lab is due to the gross negligence of Berkeley Lab. Licensee
         shall pay all costs incurred by Berkeley Lab in enforcing this
         indemnification, including reasonable attorney fees. The indemnity set
         forth herein shall apply only if Licensee shall have been given an
         opportunity, to the maximum extent afforded by applicable laws, rules,
         or regulations, to participate in and control its defense. No
         settlement for which Licensee would be responsible shall be made
         without Licensee's consent unless required by final decree of a court
         of competent jurisdiction.

20.2.    Licensee, at its sole expense, shall insure its activities in
         connection with the work under this Agreement and obtain and keep in
         force Comprehensive or Commercial Form General Liability Insurance
         (contractual liability and products liability included) with limits as
         follows:

         20.2.1.  Each Occurrence                           $[*** Redacted]

         20.2.2.  Products/Completed Operations Aggregate   $[*** Redacted]

         20.2.3.  Personal and Advertising Injury           $[*** Redacted]

         20.2.4.  General Aggregate (commercial form only)  $[*** Redacted]

20.3.    The coverages and limits referred to in this Article 20 do not in any
         way limit the liability of Licensee. Licensee shall furnish Berkeley
         Lab with certificates of insurance, including renewals, evidencing
         compliance with all requirements at least 30 days prior to the first
         commercial sale, use, practice or distribution of a Licensed Product.

         20.3.1.  If such insurance is written on a claims-made form, coverage
                  shall provide for a retroactive date of placement on or
                  before the Effective Date.

         20.3.2.  Licensee shall maintain the general liability insurance
                  specified during: (a) the period that the Licensed
                  Product is being commercially distributed or sold by Licensee
                  or by a sublicensee or agent of Licensee, and (b) a reasonable
                  period thereafter, but in no event less than five years.

20.4.    The insurance coverage of paragraph 20.2 must:

         20.4.1.  Provide for 30-day advance written notice to Berkeley
                  Lab of cancellation or of any modification.

         20.4.2.  Indicate that DOE, "The Regents of the University of
                  California" and its officers, employees, students, agents, are
                  endorsed as additional insureds.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                    13 of 19
<PAGE>

         20.4.3.  Include a provision that the coverages are primary and do not
                  participate with, nor are excess over, any valid and
                  collectible insurance or program of self-insurance carried or
                  maintained by Berkeley Lab.

                               21. LATE PAYMENTS

21.1     If Licensee does not make a payment to Berkeley Lab when due, Licensee
         shall pay to Berkeley Lab such reasonable administrative fees and
         interest as Berkeley Lab generally charges third parties on overdue
         accounts.

                                   22. NOTICES

22.1.    Any payment, notice or other communication this Agreement requires or
         permits either party to give must be in writing to the appropriate
         address given below, or to such other address as one party designates
         by written notice to the other party. The parties deem payment, notice
         or other communication to have been properly given and to be effective
         (a) on the date of delivery if delivered in person; (b) on the fourth
         day after mailing if mailed by first-class mail, postage paid; (c) on
         the second day after delivery to an overnight courier service such as
         Federal Express, if sent by such a service; or (d) upon confirmed
         transmission by telecopier. The parties' addresses are as follows:

                  For Berkeley Lab:

                  Lawrence Berkeley National Laboratory
                  Technology Transfer Department
                  Mailstop 90-1070
                  One Cyclotron Road
                  Berkeley, California 94720
                  Attention: Licensing Manager
                  Fax:   510/486-6457
                  Telephone: 510/486-6467
                  e-mail: viwolinsky@lbl.gov

                  For Licensee:

                  Nanosys, Inc.
                  2625 Hanover St.
                  Palo Alto, Ca 94304
                  Attention: Larry Bock, CEO
                  Fax: 650/ 846-2501
                  Telephone: 650/ 846-2500
                  e-mail: lbock@nanosysinc.com

                  With a copy to:

                  Michael O' Donnell, Esq.
                  Wilson, Sonsini, Goodrich and Rosati
                  650 Page Mill Road
                  Palo Alto, CA 94304

                                    14 of 19

<PAGE>

                              23. U.S. MANUFACTURE

23.1.    Licensee shall have Licensed Products produced for sale in the United
         States manufactured substantially in the United States so long as
         Licensee has current exclusive rights in the Field of Use.

                               24. PATENT MARKING

24.1.    Licensee shall mark all Licensed Products made, used or sold under this
         Agreement, or their containers, in accordance with the applicable
         patent marking laws and to the extent reasonably practicable.

                     25. GOVERNMENT APPROVAL OR REGISTRATION

25.1.    If the law of any nation requires that any governmental agency either
         approve or register this Agreement or any associated transaction,
         Licensee shall assume all legal obligation to do so. Licensee shall
         notify Berkeley Lab if it becomes aware that this Agreement is subject
         to a U.S. or foreign government reporting or approval requirement.
         Licensee shall make all necessary filings and pay all costs, including
         fees, penalties, and all other costs associated with such reporting or
         approval process.

                             26. EXPORT CONTROL LAWS

26.1.    Licensee shall observe all applicable United States and foreign laws
         and regulations with respect to the transfer of Licensed Products and
         related technical data, including, without limitation, the
         International Traffic in Arms Regulations (ITAR) and the Export
         Administration Regulations.

                                27. FORCE MAJEURE

27.1.    If a party's performance required under this Agreement is rendered
         impossible or unfeasible due to any catastrophes or other major events
         beyond its reasonable control, including, without limitation, the
         following, the parties are excused from performance: war, riot, and
         insurrection; laws, proclamations, edicts, ordinances or regulations;
         strikes, lockouts or other serious labor disputes; and floods, fires,
         explosions, or other natural disasters. When such events abate, the
         parties' respective obligations under this Agreement must resume.

                                28. MISCELLANEOUS

28.1.    The headings of the several sections are inserted for convenience of
         reference only and are not intended to be a part of or to affect the
         meaning or interpretation of this Agreement.

28.2.    This Agreement is not binding upon the parties until it is signed below
         on behalf of each party.

28.3.    No amendment or modification hereof shall be valid or binding upon the
         parties unless made in writing and signed on behalf of each party.

                                    15 of 19
<PAGE>

28.4.    This Agreement embodies the entire and final understanding of the
         parties on this subject. It supersedes any previous representations,
         agreements, or understandings, whether oral or written.

28.5.    If a court of competent jurisdiction holds any provision of this
         Agreement invalid, illegal or unenforceable in any respect, this
         Agreement must be construed as if that invalid or illegal or
         unenforceable provision is severed from the Agreement, provided,
         however, that the parties shall negotiate in good faith substitute
         enforceable provisions that most nearly effect the parties' intent in
         entering into this Agreement.

28.6.    This Agreement must be interpreted under California law, without giving
         effect to any choice of law rules that would result in the application
         of laws of any jurisdiction other than California.

Berkeley Lab and Licensee execute this Agreement in duplicate originals through
their duly authorized respective officers in one or more counterparts, that
taken together, are but one instrument.

THE REGENTS OF THE UNIVERSITY OF                NANOSYS, INC.
CALIFORNIA, THROUGH THE ERNEST
ORLANDO LAWRENCE BERKELEY NATIONAL
LABORATORY

By /s/ Piermaria Oddone                         By  /s/ Lawrence Bock
   ---------------------------------               -----------------------------
             (Signature)                                  (Signature)

By Piermaria Oddone                             By Lawrence Bock
                                                        (Please Print)

Title Deputy Laboratory Director                Title President

Date 10/11/02                                   Date 10/15/02

         Approved as to form

         /s/ Glenn R. Woods
         ---------------------------
         GLENN R. WOODS
         LAWRENCE BERKELEY NATIONAL LABORATORY

                                    16 of 19
<PAGE>

                                    EXHIBIT 1

                          LICENSED (EXCLUSIVE) PATENTS

<TABLE>
<CAPTION>
BERKELEY LAB
CASE NUMBER                         PATENT APPLICATION/ PATENT
<S>               <C>
IB-1576           US Patent Application Serial Number 09/702,219, filed
                  10/30/00, entitled, A non-hydrolytic single-precursor approach
                  to surfactant-capped nanocrystals of transition metal oxides
                  by A. Paul Alivisatos and Joerg Rocken-berger

IB-1576A          US Patent Application Serial Number 09/721,126, filed
                  11/22/00, entitled A Process for Making Surfactant Capped
                  Nanocrystals, by A. Paul Alivisatos and Joerg Rockenberger

IB-1402           [*** Redacted]
</TABLE>

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                    17 of 19
<PAGE>

                                    EXHIBIT 2

                        LICENSED (FOU EXCLUSIVE) PATENTS

<TABLE>
<Caption>
BERKELEY LAB
CASE NUMBER                         PATENT APPLICATION/ PATENT
<S>               <C>
IB-1330JP         Japanese Patent Application Number 11-80598, filed 3/24/99,
                  entitled, Semiconductor nanocrystal probes for biological
                  applications and process for making and using such probes, by
                  Shimon Weiss, Marcel Bruchez, Jr., and A. Paul Alivisatos

IB-1330A-EPO      European Patent Organization Application number 00915944.3,
                  filed 2/28/00, entitled Semiconductor nanocrystal probes for
                  biological applications and process for making and using such
                  probes, by Shimon Weiss, Marcel Bruchez, Jr., and A. Paul
                  Alivisatos

IB-1330A-CA       Canadian Patent Application Number pending, filed 8/10/01,
                  entitled Semiconductor nanocrystal probes for biological
                  applications and process for making and using such probes, by
                  Shimon Weiss, Marcel Bruchez, Jr., and A. Paul Alivisatos

IB-1330A-JP       Japanese Patent Application Number pending, entitled
                  Semiconductor nanocrystal probes for biological applications
                  and process for making and using such probes, by Shimon Weiss,
                  Marcel Bruchez, Jr., and A. Paul Alivisatos

IB-1330B          US Patent Application Serial Number 09/349,833 filed 7/8/1999,
                  entitled Semiconductor nanocrystal probes for biological
                  applications and process for making and using such probes, by
                  Shimon Weiss, Marcel Bruchez, Jr., and A. Paul Alivisatos

IB-1330C          US Patent Application Serial Number 09/781,621, filed
                  2/12/2001, entitled Semiconductor nanocrystal probes for
                  biological applications and process for making and using such
                  probes, by Shimon Weiss, Marcel Bruchez, Jr., and A. Paul
                  Alivisatos

IB-1330D          US Patent Application Serial Number 09/865,130, filed
                  5/24/2001, entitled Semiconductor nanocrystal probes for
                  biological applications and process for making and using such
                  probes, by Shimon Weiss, Marcel Bruchez, Jr., and A. Paul
                  Alivisatos

IB-1330E          US Patent Application Serial Number pending,, filed 5/24/2002,
                  entitled Organo luminescent semiconductor nanocrystal probes
                  for biological applications and process for making and using
                  such probes, by Shimon Weiss, Marcel Bruchez, Jr., and A. Paul
                  Alivisatos

IB-1330F          US Patent Application Serial Number pending,, filed 5/24/2002,
                  entitled Semiconductor nanocrystal probes for biological
                  applications and process for making and using such probes, by
                  Shimon Weiss, Marcel Bruchez, Jr., and A. Paul Alivisatos

</TABLE>

                                    18 of 19

<PAGE>
<TABLE>
<S>               <C>

IB-1783P*         US provisional patent application, serial number 60/346,253,
                  filed 10/24/01, entitled, Quantum Rod Liquid Crystals and
                  Process of Making, by A. Paul Alivisatos and Liang-shi Li

IB-1773P*         U.S. provisional patent application, serial number 60/335,435,
                  filed 11/30/01, entitled Synthesis of Branched 3-Dimensional
                  Inorganic Nanocrystals and Inorganic Dendrimers, by A. Paul
                  Alivisatos, Erik Scher, and Liberato Manna

IB-1527A          US Patent Number 6,225,198, issued May 1, 2001, entitled
                  Process for Forming Shaped Group II-VI Semiconductor
                  Nanocrystals, and Product Formed Using Process, by A. Paul
                  Alivisatos, Xiaogang Peng, and Liberato Manna

IB-1527B          US Patent Number 6,306,736, issued October 23, 2001, entitled
                  Process for Forming Shaped Group III-V Semiconductor
                  Nanocrystals, and Product Formed Using Process, by A. Paul
                  Alivisatos, Xiaogang Peng, and Liberato Manna.

IB-1330           US Patent Number 5,990,479, issued November 23, 1999, entitled
                  Organoluminescent semiconductor nanocrystal probes for
                  biological applications and process for making and using such
                  probes, by Shimon Weiss, Marcel Bruchez, Jr., and A. Paul
                  Alivisatos

IB-1330A          US Patent Number 6,207,392, issued March 27, 2001, entitled
                  Semiconductor nanocrystal probes for biological applications
                  and process for making and using such probes by Shimon
                  Weiss, Marcel Bruchez, Jr., and A. Paul Alivisatos

CIB-1030          US Patent Number 5,537,000, issued July 16, 1996, entitled
                  Electroluminescent Devices Formed Using Semiconductor
                  Nanocrystals as an Electron Transport Media and Method of
                  Making Such Electroluminescent Devices, by A. Paul Alivisatos
                  and Vicki L. Colvin

IB-866A           US Patent Number 5,751,018, issued May 12, 1998, entitled
                  Semiconductor Nanocrystals Covalently Bound to Solid Inorganic
                  Surfaces Using Self-Assembled Monolayers, by A. Paul
                  Alivisatos and Vicki L. Colvin

IB-865            US Patent Number 5,262,357, issued November 16, 1993, entitled
                  Low Temperature Thin Films Formed Via Nanocrystal Precursors,
                  by A. Paul Alivisatos and Avery N. Goldstein

IB-864A           US Patent Number 5,505,928, issued April 9,1996, entitled
                  Preparation Of III-V Semiconductor Nanocrystals, by A. Paul
                  Alivisatos and Michael A. Olshavsky
</TABLE>

---------------
* If Berkeley Lab within 6 months from the Effective Date has not licensed to
any third party the exclusions to the Field of Use for these Berkeley Lab case
numbers IB-1773 and IB-1783 or provided written notice to Licensee that Berkeley
Lab is in the process of doing so, then such cases shall automatically become
Licensed (Exclusive) Patents.

                                    19 of 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]